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1.1 Immune system of the gastrointenstinal tract 
The gastrointestinal (GI) tract is constantly exposed to a wide range of stimuli, i.e. environmental 
antigens, the commensal microbiota or pathogenic bacteria. A very important role of managing an 
appropriate immune response to these foreign antigens is fulfilled by the gut-associated lymphoid 
tissue (GALT). This independently functioning system is the most prominent collection of lymphoid 
tissues and consists of organized compartments, e.g. Peyer’s patches (PPs) and mesenteric lymph 
nodes (MLNs), as well as diffusely scattered immune cells located in the gut mucosa (1, 2). The GI 
tract is a major site of immune modulation, considering the fact that approximately 70% of the entire 
immune system is located within the GALT, and almost 80% of IgA-producing plasma cells reside in 
the lamina propria (LP) of the gut (3). Thus, disturbance of the balance between tolerance and 
immunity can lead to serious chronic conditions, e.g. inflammatory bowel disease (IBD) or food 
allergies (4, 5).  
 
1.1.1 Intestinal barrier 
To manage the constant presence of potentially harmful antigens and to maintain the physiological 
organ function, the GI tract has developed various mechanisms to act as a physical and biochemical 
barrier and protect the gut homeostasis (6). The intestinal mucosa is the major site of immunological 
processes in the gut. It is composed of a single layer of epithelial cells, the underlying LP and the 
muscular mucosa (7). The intestinal epithelium plays a crucial role in the host defense against foreign 
antigens and pathogens by providing a mechanical barrier function. At the same time, the epithelial 
layer must allow absorption of dietary nutrients. Intestinal epithelial cells (IECs) comprise absorptive 
epithelial cells, goblet cells, which synthesize and release mucin, as well as Paneth cells, which 
secrete anti-microbial peptides (AMPs) (8). Enterocytes which represent the most prominent cell 
type of the epithelial monolayer produce proteins forming the glycocalix as well as anti-microbial 
agents, such as β-defensins. In some regions, enterocytes are interspersed with M cells, which are 





underlying GALT. Restriction of the passage of even the smallest molecules into the mucosa is the 
main role of tight junctions  
(TJs), which seal the intercellular spaces on the luminal surface (9–11). Another component of the 
physical barrier is the mucus layer covering the gut epithelium on the luminal side. The mucus layer 
contains mucin glycoproteins that are produced by intestinal secretory cells, the goblet cells. The 
mucus layer plays a crucial role in preventing pathogen infection and intestinal inflammation 
considering the large number of microorganisms residing in the gut. The most abundant component 
of the mucus is mucin 2 (MUC2), which by its large net-like polymers organizes the layer to serve as 
protective system against pathogenic bacteria (12). It has been shown that MUC2-deficient mice 
develop spontaneous colitis and have a predisposition for inflammation-induced colorectal cancer 
(13, 14). A variety of AMPs produced by Paneth cells serve as chemical barrier to protect the gut 
homeostasis. These small oligopeptides have a broad spectrum antimicrobial activity that contributes 
to the restriction of bacterial growth (15). Considering its extensiveness and complex function, any 
defect in or disintegration of the intestinal barrier can lead to disruption of the mucosal immune 
homeostasis and consequently to uncontrolled inflammation.  
 
1.1.2 Regulation of gut homeostasis by the innate and adaptive immune system 
The immune system has evolved various mechanisms to protect the host from invasion by 
pathogenic microorganisms. There are specialized innate and adaptive immune components present 
in the intestinal mucosa that contribute to the development of appropriate immune responses 
towards the numerous challenges. On the other hand, gut homeostasis depends on tolerance of the 
immune system towards microbial and environmental factors, such as food components. The innate 
immune system provides an immediate reaction to pathogenic invaders in the intestine. This includes 
the epithelial barrier and several types of antigen-presenting cells (APC). The APCs found in the gut 
mucosa encompass myeloid cells, such as dendritic cells (DCs), macrophages and regulatory myeloid 
(Mreg) cells. DCs promote immune tolerance against intestinal microbiota, as well as protective 
immune responses against pathogens. Thanks to the ability to recognize pathogen-associated 
molecular patterns (PAMPs) by pattern recognition receptors (PRRs), the innate immune system is 
involved in the activation of the DCs, which leads to development of T helper (Th)1/Th17 cells (16). 
Intestinal macrophages suppress the production of pro-inflammatory cytokines (e.g. interleukin-12 
(IL-12) and TNF-α) by secreting large amounts of IL-10 in response to the commensal microbiota. 
Moreover, macrophage-derived IL-10 maintains expression of FoxP3 in regulatory T (Treg) cells. Thus, 





intestinal microbiota (17). Other important contributors in regulating intestinal inflammation are 
Mreg cells, which inhibit proliferation of T cells by a cell-cell-contact-dependent mechanism (18). It 
has been shown that disruption of the function of innate myeloid cells leads to excessive activation 
of innate immune responses and can result in the development of IBD (19). Next to innate myeloid 
cells, another cell population responsible for immune homeostasis is innate lymphoid cells (ILCs). 
They are considered significant contributors to the maintenance of intestinal barrier function, to the 
induction of inflammatory reactions as well as the regulation of tissue repair. Type-3 ILCs seem to 
play a special role due to production of IL-22 in the gut, which stimulates production of AMPs and 
mucus in epithelial cells (20). Although the precise underlying mechanism remains unclear, the role 
of aryl hydrocarbon receptor (AhR) has been reported as essential for maintenance of ILC3 
homeostasis and their production of IL-22 (21, 22). AhR is a ligand-dependent transcription factor 
expressed by different types of immune cells (i.e. ILC3, Th17, Th22, Macrophages) (23). It can be 
activated by various natural and synthetic ligands, including catabolites derived from gut microbiota 
or nutrition, thus it significantly contributes to regulation of intestinal physiology (24).  
The innate immune system not only provides an acute non-specific defense, but also plays a crucial 
role in the regulation of adaptive immune responses. Adaptive immunity in the gut depends on 
lymphocytes that play a key role in inducing specific and memory immune responses. The intestinal 
mucosa contains the greatest population of T cells in the body (25). T cell populations found in the 
gut are highly heterogeneous and upon stimulation, they become activated, secrete cytokines and 
influence many other cell types present in the local environment. There is a large population of CD4+ 
T cells present in the LP that mostly comprises effector and memory T cells. For gut homeostasis, the 
number and activity of effector T cells, including Th1 and Th17 cells, have to be strictly regulated by 
various mechanisms. Increased numbers of these cells were found in the gut mucosa of IBD patients, 
emphasizing the importance of controlling their activity (26). On the other hand, appropriate Th1 and 
Th17 responses are crucial in the defense against invading pathogens. Th1 cells produce interferon 
(IFN)- essential for the activation of macrophages, while Th17 cytokines, such as  
IL-22, stimulate the production of AMPs and manage the integrity of the epithelial barrier (27). 
FoxP3+ Treg cells play a crucial role in the suppression of exaggerated immune responses driven by 
effector T cells. This cell subset controls the development of inflammation by producing anti-
inflammatory cytokines, i.e. IL-10 and transforming growth factor (TGF)-β. Treg cells-derived  
IL-10 inhibits production of Th1 cytokines. Thus, IL-10-deficient mice develop spontaneous colitis 
with increased effector T cell activity (28). Moreover, Treg cells provide several mechanisms that 
inhibit APC function (29). Next to T cells, large numbers of plasma B cells are present in the normal 





great majority of them are Immunoglobulin A (IgA)-producing plasma cells secreting the primary 
antibody isotype of the mucosal humoral immune system (30, 31). 
 
1.1.3 Secretory IgA 
Polymeric IgA (secretory IgA, sIgA) is the major immunoglobulin present at mucosal surfaces of 
mammals. The sIgA is produced by plasma cells in the LP and has a significantly different molecular 
structure than IgA antibodies found in the serum or tissues. This immunoglobulin serves as one of 
the primary factors preventing invasion of pathogens into the mucosa (32). The most commonly 
proposed mechanism by which sIgA blocks microbial pathogens and toxins from entering mucosal 
epithelial cells is called immune exclusion. The sIgA possesses a special ability to recognize polyvalent 
antigenic epitopes on the surface of bacteria or viruses and subsequently agglutinate the antigens in 
the intestinal lumen. Consequently, the possible invaders lose their potential to adhere to or 
penetrate the epithelium. (33). Moreover, sIgA plays a crucial role in presenting the contents of the 
microbiota to the immune system. Therefore, its contribution in maintaining homeostasis in the gut 
is essential. Immune complexes of sIgA and commensal bacteria are transferred from the lumen into 
the mucosa, and the bacterial components are selectively presented to tolerogenic DCs that produce 
anti-inflammatory IL-10. Thus, a tolerogenic immune response to the microbiota is induced (34).  
 
1.1.4 Impact of the microbiota on immune homeostasis in the gut 
Intestinal immune system develops and stabilizes within first years of life. Additionally, adequate 
host defense mechanisms need to be established as well. Therefore, initial bacterial colonization is 
required to stimulate the protective function of the gut immune system (35). It has been confirmed 
that a proper development as well as optimal function of the mucosal immune system depends on 
colonization with commensal microbiota. In healthy individuals, the intestinal microbiota includes 
over 1.000 species of bacteria, which contribute to the homeostasis in the gut. Presence of the 
abundant bacterial community is essential for proper digestion and absorption of nutrients, but also 
prevention of pathogenic infections (36). The immune system has evolved adaptations to protect the 
symbiotic relationship between the host and the microbiota and prevent continuous challenges 
caused by the close association of bacteria with the intestinal tissue. This mutualistic interaction is 
well-balanced in healthy organism but its disruption can result in the development of chronic 
conditions, e.g. IBD or metabolic disease  
(37). Several recent studies have demonstrated that certain commensal bacteria modulate the host 





free (GF) mouse models have become an important approach to demonstrate the critical role of the 
microbiota in the development and shaping of innate and adaptive immunity (38). Innate immune 
responses are essential for rapid elimination of pathogens, but also significantly contribute to the 
maintenance of mutualism with the gut microbiota. This relationship was first demonstrated in the 
myeloid differentiation factor 88 (MyD88)-deficient mouse model. MyD88 is a key factor in TLR (Toll-
like-receptor) signaling and its deficiency results in diminished microbial sensing. Animals lacking 
MyD88 were found to have an altered composition of the microbiota resulting in predisposition to 
intestinal inflammation (39). There is evidence proving the crucial role of the commensal bacteria for 
the development of APCs. GF mice showed a decreased number of intestinal DCs, but colonization of 
these animals with Escherichia coli caused recruitment of DCs to the intestine (40). The microbiota 
also contributes to the regulation of anti-inflammatory functions of intestinal macrophages by 
controlling the production of IL-10 (41), which is mediated, among others, by  AhR. It was shown, 
that AhR-deficient macrophages have an impaired ability to secrete IL-10 upon LPS stimulation, 
therefore the ligand-activated AhR is required for optimal IL-10 production in TLR-stimulated 
macrophages (42). Moreover, intestinal macrophages in GF mice appear to have impaired key 
functions, such as phagocytosis and chemotaxis (43, 44). The microbiota also influences the barrier 
function and integrity of the intestinal epithelium by regulating the expression of antimicrobial 
factors on IECs, which was demonstrated in GF mice. IECs in these mice showed decreased 
proliferation and reduced expression of genes for antimicrobial factors (45). The acquired immunity 
in the gut is also strongly affected by the microbiota. GF mice have a significantly reduced number of 
CD4+ T cells in the LP as well as a disturbed balance between Th1 and Th2 responses in the intestine. 
However, this imbalance is reversible by reconstitution of the gut with conventional microbiota, 
confirming that these microorganisms regulate Th-cell-mediated immunity (46). Development and 
function of Treg cells in the gut also depend on the presence of intestinal bacteria. It was shown that 
the microbiota promotes development of a fully functional Treg population, whereas GF mice have 
significantly reduced numbers of these cells in the colonic LP (47). The gut resident intestinal 
microbiota is a major driving force for mucosal IgA production. There are studies proving that GF 
animals have a reduced number of IgA-secreting plasma cells. Moreover, these cells do not appear in 
neonates before they have been colonized with a commensal microbiota (48).  
 
1.1.5 Interleukin-22 
IL-22 is a recently discovered cytokine possessing multifaceted and unique biological properties. It 





system, e.g. various CD4+ T cells (Th17 and Th22 cells), type 3 ILCs, natural killer (NK) cells and DCs 
(49). IL-22 is involved in many processes, i.e. cell proliferation and survival, wound healing, tissue 
regeneration, host defense and inflammatory reactions (50). The IL-22-receptor  
(IL-22R) is a heterodimer, composed of the subunits IL-22-receptor-alpha (IL-22RA1) and IL-10-
receptor 2 (IL-102R). While IL-10R2 is constitutively expressed in various cells throughout the body, 
IL-22RA1 expression is restricted almost exclusively to epithelial cells (51). Binding of IL-22 to the 
receptor allows regulation of epithelial cells, endothelial cells, fibroblasts and other stromal cells’ 
responses by immune cells. This mechanism plays a crucial role at barrier surfaces, where epithelial 
cells are a critical component of immune responses (52). IL-22 signaling via the receptor complex 
leads to phosphorylation and activation of the transcription factor Signal transducer and activator of 
transcription 3 (STAT3) (53). STAT 3 activation results in expression of tissue-specific genes, including 
both anti-inflammatory, as well as proinflammatory cytokines, e.g. IL-10, IL-6 and IL-1β (54). This 
significantly contributes to the maintenance of homeostasis as well as wound healing in the intestinal 
epithelium. Moreover, it has been shown that via this signaling pathway, IL-22 inhibits cell apoptosis 
and promotes cell proliferation and regeneration. For example, IL-22 induced hepatocyte cells 
survival and proliferation by activating STAT3 phosphorylation in vitro (55). Furthermore, IL-22 
induces production of AMPs (56, 57) thanks to a cross talk between commensal bacteria and AhR. 
Microbiota can provide AhR ligands in order to stimulate IL-22 production by ILC3, which has been 
shown to be impaired by lack of AhR (58). It is difficult to assign a distinct tissue protecting or 
damaging function to IL-22. On the one hand, IL-22 was reported to play a protective role in colitis by 
regulating production of mucin by goblet cells (59). Additionally, IL-22 stimulates intestinal epithelial 
cells to express mucus proteins (e.g. MUC1), antimicrobial proteins (e.g. Reg3) and cell adhesion 
proteins (e.g. Claudin-1), which mediate the barrier function of the epithelial layer (60). On the other 
hand,  
IL-22 was shown to be involved in the pathogenesis of psoriatic skin inflammation (61). Several 
studies have shown that patients with IBD have increased IL-22 levels in the serum and in disease-
related lesions in the colon (62, 63). It has also been demonstrated that local gene expression of IL-22 
in the colon of mice with colitis led to amelioration of inflammation (59). Moreover, administration 
of IL-22 to healthy mice resulted in neutralization of lipopolysaccharide-binding protein (LPS) and 
alleviation of inflammation, suggesting that IL-22 has a potential to act as an anti-inflammatory 







1.2 Influence of antibiotic therapy on gut microbiota and immunity 
The gut microbiota plays a fundamental role in development and differentiation of the host’s fully 
operant immune system. For over half a century, antibiotics have become a leading effective weapon 
against bacterial infections. However, a widespread and constantly increasing intake of antibiotics in 
modern societies has probably been the major factor leading to disruption of the commensal 
populations in many individuals. Given its role for a functional immune system, these changes result 
in multiple health problems e.g. increased susceptibility to infections, allergies, and possibly other 
diseases (65). Most of the commonly used antibiotics have a broad spectrum of action. Thus, they 
impact not only pathogenic bacteria, but also the physiological microbiota. This can lead to critical 
consequences, since a stable composition of the gut microbiota acts as a natural barrier against 
invading pathogens. Consequently, antibiotic-induced dysbiosis leads to reduced colonization 
resistance against pathogenic bacteria, for instance enteropathogenic strains like Clostridium difficile 
(C. difficile) or antibiotic-resistant Enterococcus. Moreover, loss of diversity and certain important 
taxa, as well as alterations in metabolic capacity are common issues caused by the shift in gut 
microbiota composition (66, 67). C. difficile infection typically occurs very rarely, but it has been 
demonstrated that alterations of the intestinal microbiota have a strong association with preceding 
antibiotic treatment (68). Another important concern is antibiotic therapy in children, considering 
that even short-term administration in the first two years of life may trigger long-lasting disturbance 
of the gut microbiota and therefore impaired mutualism with the host (69). There has been a 
growing recognition of significant associations between inflammatory and autoimmune diseases and 
the exposure to antibiotics during early life, which is obviously a crucial period for development, as 
well as formation of the immune system and tolerance (70). Hviid et al. showed that children 
exposed to antibiotics in early childhood had an increased risk of developing Crohn’s Disease (CD) 
(71). Antibiotics have a significant impact on the intestinal barrier. It has been shown that treatment 
with metronidazole led to increased numbers of macrophages and NK cells in the LP. Moreover, a 
reduced expression of the most prominent component of the mucus layer, MUC2, was observed. 
Reduction of mucus layer integrity resulted in accelerated attachment of the enteric pathogen 
Citrobacter rodentium (C. rodentium) in mice (72). The microbiota impacts host immunity by 
activating microorganism-associated molecular pattern  
(MAMP) recognition receptors, i.e. TLRs and NOD-like receptors (NLRs). Signaling via these receptors 
plays an important role in the maintenance of gut homeostasis. Consequently, reduction of the 
amount of MAMPs caused by microbiota depletion after antibiotic therapy can inhibit regulation of 
innate immune responses (73). Beyond antimicrobial defenses, antibiotics can impair the activity of 





intestine (74). Furthermore, administration of a combination of ampicillin, gentamicin, 
metronidazole, neomycin, and vancomycin resulted in decreased frequency of IFN--expressing T 
cells in the gut (75). Various clinical observations confirm that development and course of IBD is 
strongly related to dysbiosis in the intestinal microbiota. Most studies demonstrated reduced 
diversity of the gut microbiota, but also increased instability of microbiota composition was shown in 
patients with IBD (76). There are several examples demonstrating how alterations in the gut 
microbiota may be involved in the pathophysiology of IBD. Metabolites of the commensals support 
epithelial barrier function and the immune system of the host. A metagenomics analysis of gut 
microbiota from IBD patients revealed an increase in genes involved in the oxidative stress pathway, 
denoting it as an origin for intestinal inflammation (77). Some patients with ulcerative colitis (UC) 
demonstrate an increase of sulfate-reducing bacteria (SRB), which produce hydrogen sulfide that is 
toxic to the epithelial cells, thereby causing mucosal inflammation (78). Furthermore, it has been 
shown that in IBD patients, the number of bacteria in the mucus layer is elevated, implying defective 
mucosal barrier function (79). However, it is still unclear whether dysbiosis is a cause or a 
consequence of intestinal inflammation in IBD.  
 
 
1.3 Inflammatory bowel disease (IBD) 
IBD, including CD and UC, is a chronic-relapsing disorder of the GI tract, for which an increasing 
incidence is observed worldwide. Although these diseases have low mortality, the affected patients 
suffer greatly from diarrhea, weight loss, chronic pain and reoccurring bleeding incidents. Moreover, 
these patients have an increased risk of developing of colorectal  
cancer (80, 81). CD and UC are two main manifestation forms of IBD and can be distinguished by 
significant differences in clinical symptoms. While the tissue inflammation in UC is limited to the 
outer mucosa of the colon, in case of CD, inflammation can affect the entire GI tract, as well as all 
tissue layers. Moreover, in both cases, additional manifestations, mainly located in eyes, skin, liver 
and joints can also occur (82, 83).  
The clinical symptoms of both diseases have been described extensively, however the  
pathophysiology of the inflammatory reaction have been only partially understood so far. Apart from 
genetic predisposition and environmental factors, an inappropriate immune response to the 
commensal flora is discussed as a major driving factor (84, 85). Approximately 1.4 millions of 
Americans are currently affected by IBD and a significant increase of incidence has been observed 





regions with low occurrence of IBD, gain an increased risk of developing the disease after settling in 
countries with higher prevalence, especially among first-generation children (86, 87). Thus, there is 
some evidence indicating a critical role of environmental factors in development of the disease.  
Next-generation sequencing (NGS) technologies allowed comprehensive investigation of genetic 
features of the host conditioning increased susceptibility to IBD. Several studies demonstrated, that 
some of IBD-associated genes are involved in maintenance of intestinal barrier, activation of mucosal 
immune response as well as detection of microorganisms (88).  For instance, mutations of innate 
immune receptor nucleotide oligomerization domain containing 2 (NOD2) were the first ones 
associated with IBD. NOD2 is a general sensor of microbial cell wall component muramyl dipeptide 
present on all Gram-negative and Gram-positive bacteria and therefore essential for detection of 
these microorganisms (89). Furthermore, mutations of IL-23 receptor (IL-23R) are also commonly 
found in patients with CD and UC. These lead to impaired signal transmission by proinflammatory 
cytokine IL-23 and therefore disturbed activation of T cells and macrophages in the intestinal mucosa 
(90).  
It seems that the combination of genetic and environmental factors triggers modifications in 
epithelial barrier function, which facilitate inflow of luminal antigens into the gut wall, followed by an 
excessive and inappropriate immune response, promoted by mucosal immune cells, such as T cells, 
macrophages and type 3 ILCs (84).  
 
 
1.4 The immune response to Salmonella enterica infection 
Salmonella enterica (S. enterica) is a facultative intracellular pathogen found in the intestinal tract of 
various host species. These Gram-negative bacteria are causative agents of infections with various 
symptoms, ranging from self-limiting gastroenteritis to typhoid fever (91). Salmonellae are usually 
consumed with contaminated water or food. This pathogen can use several different mechanisms to 
enter the intestinal mucosa. A main route of entry is through M cells, which transport antigens from 
the lumen to the LP. Salmonella can also actively invade enterocytes using its virulence-associated 
type-3 secretion system encoded by Salmonella pathogenicity Island 1 (SPI-1) (92). Finally, invasion 
occurs through resident DCs that extend protrusions into the gut lumen to sample luminal antigens. 
Salmonella penetration triggers disruption of the mucosal barrier, thus facilitating entry of additional 
bacteria via enterocytes (93). Initial interaction of the pathogen with epithelial cells induces the early 
immune response in PPs and MLNs, which sparks a massive inflammatory reaction featuring 





to detect various PAMPs, e.g. LPS and flagellin expressed by Salmonella, via TLRs. As a response to 
recognition of PAMPs, DCs increase the expression of MHC II and costimulatory molecules, which 
allows efficient antigen presentation to naïve CD4+ T cells. This way, DCs contribute to a necessary 
induction of adaptive immunity (94). There are several studies that demonstrate contribution of 
different innate cells to the restriction of early Salmonella infection. It has been shown that HIV 
patients with decreased numbers of neutrophils are more susceptible to systemic Salmonella 
infection (95). In PPs and MLNs of Salmonella-infected mice, CC-chemokine ligand 2 (CCL2), C-X-C 
motif ligand 2 (CXCL2), and CXCL9 which are involved in recruiting myeloid cells were found to be 
upregulated. Inflammatory monocytes are immediately accumulated in those tissue structures and 
produce anti-microbial factors, such as inducible Nitric Oxide Synthase (iNOS), TNF-α, and IL-1β (96). 
Development of a robust protective immune reaction against S. enterica involves both T and B cells 
(97, 98). CD4+ T cells play a crucial role in clearing primary infection. Moreover, they are essential to 
establish acquired resistance to secondary infection (99). Specific T cells become activated in PPs and 
MLNs and rapidly acquire Th1 effector functions. They are a prominent source of IFN- that further 
stimulates infected macrophages (100). Bacterial clearance requires development of Th1 cells, which 
is confirmed by the fact that mice lacking IL-12, T-bet, IFN- or IFN-R are unable to resolve 
Salmonella infection (101–103). On the other hand, there are indicators suggesting an important 
protective role of Th17 cells, which produce IL-17 and IL-22 in the intestinal mucosa in response to 
Salmonella invasion (104). However, Schulz et al. presented results indicating dispensable role of 
Th17 cells in clearance of Salmonella Enteritidis infection, as long as an effective Th1 response is 
provided. Their study in IL-12 deficient mice showed an association of IL-22, but not IL-17 activity 
with response to systemic Salmonella infection in the absence of IL-12 (Schulz et al. 2008). An 
effective immune response against Salmonella infection also relies on B lymphocyte activity and 
production of specific antibodies. Even though Salmonellae are usually tightly associated to 
phagocytic cells, there is a short period of time after apoptosis of those infected cells, where 
opsonization of bacteria with antibodies can occur, thus preventing spread of the infection (102). 
Antibodies seem to play a vital role in the presentation of Salmonella antigens to CD4+ T  
cells and consequently in the development of a Th1 response (105). Beyond a systemic antibody 
response, induced production of immunoglobulins takes place at the mucosal site. sIgA, with its 
capacity to agglutinate the pathogens in the lumen, is a prominent factor in protecting the intestinal 
barrier against pathogen invasion. It was shown that oral administration of specific IgA antibodies 
protected mice from S. Typhimurium infection in the gut (106). Moreover, it was shown that S. 







1.5 Mouse models of intestinal inflammation and the streptomycin model of Salmonella 
infection 
There is a wide range of animal models, mostly mouse models, designed to investigate intestinal 
inflammation. Despite some disadvantages, mice share multiple specific intestinal genes with 
humans. Similarities between microbiota, immune response and anatomical structure allowed the 
murine model to become the prominent choice when considering studies of intestinal injury (108). 
Inflammatory disease in the gut is a highly complex issue, therefore utilization of an appropriate 
model is necessary. There are currently over 50 animal models of IBD available, and they can be 
categorized based on the causative mechanism of inflammation (109). Among chemically-induced 
models, the dextran sulphate sodium (DSS) model is the most favored one. It’s relatively simple and 
cheap, nevertheless revealed important aspects of IBD pathogenesis (110). Furthermore, there are 
genetically engineered models that employ transgenic animals, e.g. STAT4 transgenic and HLA-
B27/β2-microglobulin transgenic mice, or knockout (KO) mice, e.g. IL-10-KO and IL-2-KO mice. These 
models are well established and provided new insights into IBD therapy, e.g. anti-Th1-targeted 
therapies, such as anti-IFN- antibodies (111). There are also T cell transfer models available, among 
which the CD4+CD45Rbhigh transfer model is the most commonly used. It has been very well described 
and highlighted Th1 and Th17 cells as key players in gut inflammation (112). Lastly, several 
spontaneous models, where mutation causes chronic gut inflammation (e.g. the C3H/HeJBir mouse 
model) were established (113). Taken together, all these approaches reflect certain aspects of colitis 
very well, but their potential to study pathophysiology of the inflammatory reaction as well as 
contribution of the gut microbiota is limited.  
Recently, some robust and reproducible bacteria-induced models of colitis have been described. In 
particular, two mouse models, i.e. a C. rodentium infection model and a model of S. enterica  
infection in streptomycin pretreated mice, are of great importance. In both mouse models, the acute 
inflammatory response in the intestinal mucosa is triggered by a well-characterized pathogen. These 
mucosal infection models allow investigation of the mechanisms associated with colonization 
resistance. Moreover, they are excellent tools for studying function of the gut mucosal system, as 
well as the importance of gut homeostasis. Thus, these models provide great input into unravelling 
the nature of inflammatory reactions in the intestine  (114).  
Since its first introduction, the S. enterica infection model has become a great tool to investigate 
innate and adaptive mucosal defense mechanisms involved in the development and course of 





the growth of gram-negative bacteria (116). It has been confirmed by several studies that 
streptomycin treatment prior to S. enterica infection eliminates the majority of the intestinal 
microbiota. This allows the pathogen to overcome the host’s resistance, colonize the mucosa and 
trigger an inflammatory reaction (117–120). Therefore, this model has been shown to be principally 
useful in studying early phases of intestinal Salmonella infection, e.g. interactions between host and 
microbiota during development of inflammatory reaction (121), description of mechanisms 
responsible for compromised resistance against pathogenic bacteria (122), or analysis of bacterial 
virulence mechanisms involved in the development of intestinal inflammation (123).  
 
 
1.6 Aim of the study 
The incidence and prevalence of chronic inflammatory bowel diseases are rising worldwide. Even 
though these disorders show a relatively low mortality, the patients suffer severely from pain, 
cramps, and bloody diarrhea (124). The pathogenesis of the inflammatory reaction in the intestine 
seems to be multifactorial, in particular genetic predisposition, environmental factors as well as an 
inappropriate immune response are discussed as main causes (125). Recently, the role of the 
microbiota and pathogenic bacteria in disturbance of intestinal immunity has been highlighted (126). 
Combination of several mechanisms seems to affect the permeability of the intestinal epithelium, 
leading to invasion of commensals and pathogens into the gut mucosa. This triggers an unrestricted 
immune response causing further destruction of the epithelial barrier. The constant influx of antigens 
sustains the immune reaction and results in chronic inflammation (82). GF mice do not develop 
clinical symptoms of intestinal disease, which confirms contribution of bacteria in the development 
of IBD. Moreover, in addition to the microbiota, pathogenic microorganisms are discussed as 
causative agents (126). For instance, infection of the intestine with Yersinia enterocolitica or 
Mycobacterium avium ssp. paratuberculosis triggers acute relapse of the disease in CD patients (127, 
128). Furthermore, clinical symptoms of Shigella spp. or Campylobacter spp. infection greatly 
resemble the pathology of UC (129). Also, involvement of Salmonella enterica in the pathogenesis of 
IBD has been discussed (130). Even though, there are multiple references indicating contribution of 
bacteria, until now there are still no fully reliable animal models available that allow investigation of 
bacteria-driven inflammation, especially in the chronic phase. The most commonly used chemically 
induced model, i.e. DSS colitis, demonstrates the destruction of mucosal barrier in the gut as a 





of IBD, however its ability to illustrate natural mechanisms, which cause onset of inflammatory 
reaction in the gut, as well as development of the chronic phase of the disease is limited (131).  
Therefore, the aim of this study was to establish a bacteria-induced mouse model, which allows 
studying the role of commensal versus pathogenic bacteria in the development of chronic intestinal 
inflammation. A previously proposed model of S. enterica infection preceded by streptomycin 
administration has mainly delivered data considering the acute phase of infection (132). In contrast, 
the mouse model developed in the present work focused on analyzing the chronic inflammatory 
reaction caused by S. enterica infection. Moreover, differences between the acute and chronic phase 
of infection should be analyzed. Additionally, it should be investigated whether treatment with 
antibiotics, i.e. streptomycin, changed the course of the systemic or mucosal immune response 
against S. enterica.  
Once the mouse model of chronic S. enterica-induced colitis is established, a special focus of this 
work was to investigate the role of IL-22 in this model since increased expression of this cytokine has 
been observed in colonic tissue of patients with IBD (63). In summary, this study aimed to provide 
significant input on the role of the microbiota and pathogens, as well as antibiotic therapy in the 
























Table 1: Used tools 
Tool Source 
20G Oral Dosing Needle 38 mm CVD 
Veterinary Instrumentation Limited; 
Sheffield, UK 
BD Microtainer SST™ Tubes 
Becton, Dickinson and Company; New Jersey, 
USA 
Cell strainers 100 µm VWR International GmbH; Dresden, Germany 
Cover slips 24x60 mm 
VWR International GmbH; Darmstadt, 
Germany 
Dako Pen 
Dako Deutschland GmbH; Hamburg, 
Germany 
Disposable Drigalski spatulas made from 
ABS 
VWR International GmbH; Dresden, Germany 
Disposable needles STERICAN® ø 0.45 x 
12mm, 26G x 1/2 
B. Braun Melsungen AG; Melsungen, 
Germany 
Disposable syringes NORM-JECT 1 ml 
Becton, Dickinson and Company; New Jersey, 
USA 
Embedding cassettes- green for biopsies 
neoLab Migge Laborbedarf-Vertriebs GmbH; 
Heidelberg, Germany 
Eppendorf-tubes (0.5 - 2 ml) Eppendorf AG; Hamburg, Germany 
FalconTM Tubes (15 ml, 50 ml) 
Greiner Bio-One GmbH; Frickenhausen, 
Germany 
Microtiter plates: PolySorpTM F96-Plates Thermo Scientific; Schwerte, Germany 
Microtome blades 
Leica Biosystems Nussloch GmbH; Nussloch, 
Germany 
Nitrile disposable gloves Ansell; Richmond, Australia 




Microscope slides Superfrost Ultra-Plus 
Gerhard Menzel GmbH; Braunschweig, 
Germany 
Pipettes, Pipetman (1-1000 µl) 
Greiner Bio-One GmbH; Frickenhausen, 
Germany 
Pipette tips (10-1000 µl) 
Greiner Bio-One GmbH; Frickenhausen, 
Germany 
Rotilabo Alufoil 
Carl Roth GmbH&Co. KG; Karlsruhe, 
Germany 
Seals for microtiter plates Laborfachhandel Schubert; Leipzig, Germany 
Sterile preparation tools Various manufacturers 
XLD-Agar plates VWR International GmbH; Dresden, Germany 
Hand dispenser Multipette plus Eppendorf AG; Wesseling-Berzdorf, Germany 
 
2.1.2 Chemicals and reagents 
 
Table 2: Used chemicals and reagents  
Chemical Source 
2-Propanol ≥ 99.5 % 
Carl Roth GmbH&Co. KG; Karlsruhe, 
Germany 
3,3′,5,5′-Tetramethylbenzidine (TMB)  Moss, Inc., Pasadena, USA 
Acetic acid ≥ 99.5 % 
Carl Roth GmbH&Co. KG; Karlsruhe, 
Germany 
Acid sulfur (96%) (H2SO4)  
Carl Roth GmbH + Co. KG, Karlsruhe, 
Germany 
Activated carbon 
Carl Roth GmbH + Co. KG, Karlsruhe, 
Germany 
Calciumchloride (CaCl2) ≥ 30 % 
Carl Roth GmbH + Co. KG, Karlsruhe, 
Germany 
Casein Sigma-Aldrich; Steinheim, Germany 




Citric acid monohydrate  
(C6H8O7 x H2O) ≥ 99.5 % 
Carl Roth GmbH + Co. KG, Karlsruhe, 
Germany 
De-ionised water  in-house production 
Disodium hydrogen phosphate 
dodecahydrate (Na2HPO4 x 12 H2O)  
Sigma-Aldrich; Steinheim, Germany 
Entellan® Merck KGaA; Darmstadt, Germany 
Eosin Y Sigma-Aldrich; Steinheim, Germany 
Ethanol ≥ 99.8 % denaturated 
Carl Roth GmbH + Co. KG, Karlsruhe, 
Germany 
Ethylene diamine tetra-acetic acid  
(EDTA) ≥ 99 % 




Sigma-Aldrich; Steinheim, Germany 
Fetal calf serum (FCS) Biochrom AG; Berlin, Germany 
Fluoroshield™ with DAPI Sigma-Aldrich; Steinheim, Germany 
Hem alum solution acid acc. to Mayer 
Carl Roth GmbH + Co. KG, Karlsruhe, 
Germany 
Hydrochloric acid, 1 M 
Carl Roth GmbH + Co. KG, Karlsruhe, 
Germany 
Hydrochloric acid, concentrated 
Carl Roth GmbH + Co. KG, Karlsruhe, 
Germany 
N,N-dimethylformamide (C3H7NO) Sigma-Aldrich; Steinheim, Germany 
Paraffin type 3 Thermo Scientific; Schwerte, Germany 
Paraffin type 6 Thermo Scientific; Schwerte, Germany 
Pararosaniline Sigma-Aldrich; Steinheim, Germany 
Periodic acid (H5IO6) Merck KGaA; Darmstadt, Germany 
Potassium chloride (KCl) 
Carl Roth GmbH + Co. KG, Karlsruhe, 
Germany 
Potassium dihydrogen phosphate (KH2PO4) 
Carl Roth GmbH + Co. KG, Karlsruhe, 
Germany 




Proteinase K Qiagen GmbH; Hilden, Germany 
Roti®-Histofix 4 % 
Carl Roth GmbH + Co. KG, Karlsruhe, 
Germany 
Sodium bicarbonate (NaCO3) 
Carl Roth GmbH + Co. KG, Karlsruhe, 
Germany 
Sodium bisulfate (Na2S2O5) Bernd Kraft GmbH; Duisburg, Germany 
Sodium chloride (NaCl) 
Th. Geyer GmbH&Co. KG; Renningen, 
Germany 
Sodium citrate dihydrate  
(C6H5Na3O7 x 2 H2O)  
Sigma-Aldrich; Steinheim, Germany 
Sodium hydroxide (NaOH) AppliChem GmbH; Darmstadt, Germany 
Streptavidin-HRP conjugate 
GE Healthcare UK Limited; Buckinghamshire, 
UK 
Streptomycin sulfate Sigma-Aldrich; Steinheim, Germany 
Tris(hydroxymethyl)-aminomethane  
(TRIS) ≥ 99.9 % 
Carl Roth GmbH + Co. KG, Karlsruhe, 
Germany 
Triton X-100 Sigma-Aldrich; Steinheim, Germany 
Tween 20 
Carl Roth GmbH + Co. KG, Karlsruhe, 
Germany 
Xylol ≥ 98 % 

















2.1.3 Buffers and solutions 
 
Table 3: Used buffers and solutions 
Name Composition 
3 % NaHCO3-PBS solution 
• 357 mM NaHCO3     
• PBS (sterile)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  
Casein blocking buffer 
• 0.5 % Casein 
• PBS 
Citrate buffer pH=6 
adjusted with HCl or NaOH 
• 5 mM C6H8O7 x H2O 
• 5 mM C6H5Na3O7 x 2 H2O 
• 0.05 % Tween 20 
• Aqua bidest. 
Eosin solution 
• 1 g Eosin Y 
• 1.7 mM acetic acid 
PBS (10x)  
pH=7.4 (w/o Ca2+/Mg2+) 
• 27 mM KCl 
• 65 mM Na2HPO4 x 12 H2O 
• 15 mM KH2PO4 
• 1.5 M NaCl 
• Aqua bidest. 
PBS-T 
• 0.05% Tween 20 
• PBS 
Protein-blocking buffer 
• 1% FCS 
• PBS-T 
Schiff’s reagent 
acc. to the European Pharmacopoeia 
(monography H-Z 2014) 
Streptomycin solution 
• 137 mM Streptomycin sulfate 
• Aqua bidest. (autoclaved) 
TRIS-EDTA-CaCl2 buffer 
pH=8 adjusted with HCl or NaOH 
• 50 mM TRIS 
• 1 mM EDTA 
• 5 mM CaCl2 
• 0.5 % Triton X-100 
• Aqua bidest. 
TRIS-EDTA-Puffer 
pH=9 adjusted with HCl or NaOH 
• 10 mM TRIS 
• 1 mM EDTA 
• 0.05 % Tween 20 











Table 4: Used unconjugated primary antibodies for Immunohistochemistry 
Antigen Original species Used 
concentration 
Source 
CD3 Rabbit (polyclonal) 1.2 µg/ml Dako Denmark A/S; Glostrup, 
Denmark 
Claudin-1 Rabbit (polyclonal) 1 µg/ml LSBio; Seattle, WA, USA 
IFN- Rabbit (polyclonal) 1 µg/ml Biorbyt Ltd.; Cambridge, UK 
IgA Goat (polyclonal) 0.2 µg/ml Southern Biotech; Birmingham 
AL, USA 
IL-22 Rabbit (polyclonal) 5 mg/ml Abcam plc; Cambridge, UK 
RORt Mouse (monoclonal) 5 µg/ml 
BD Bioscience;   
San Diego, CA, USA 
 
 
Table 5: Used secondary antibodies for Immunohistochemistry 
Target  
protein 




Goat IgG Rabbit Biotin 3 µg/ml 
Jackson ImmunoResearch  
Europe Ltd; Suffolk, UK 
Rabbit IgG Goat Biotin 2 µg/ml 
Life Technologies/ 
Thermo Fisher Scientific; 
Waltham, MA, USA 
Mouse IgG Goat Biotin 2.8 µg/ml 
Jackson ImmunoResearch  
Europe Ltd; Suffolk, UK 
Rat IgG Donkey Biotin 1.6 µg/ml 
Jackson ImmunoResearch  












Table 6: Used detection antibodies for ELISA 

























Birmingham, AL, USA 










Table 7: Used devices 
Name Source 
Analytical scale CPA 324 S Sartorius AG; Göttingen, Germany 
AxioScan.Z1 Carl Zeiss Jena GmbH; Jena, Germany 
Clean bench Herasafe™ KS (NSF)  
Class II 
Thermo Scientific; Schwerte, Germany 
Cooling plate COP30 Medite; Burgdorf, Germany 
Euthanasia box Agnthos AB; Lidingö, Sweden 
High-purity water facility Thermo Scientific; Schwerte, Germany 
Microplate reader TECAN Safire2TM Tecan Group Ltd.; Männedorf, Switzerland 
Microplate washer TECAN 96 Plate 
Washer™ 
Tecan Group Ltd.; Männedorf, Switzerland 
Paraffin-embedding station Leica EG1150H 
Leica Biosystems Nussloch GmbH; Nussloch, 
Germany 
pH-Meter SI-Analytics GmbH; Mainz, Germany 




Precision scale Extend Sartorius AG; Göttingen, Germany 
Refrigerated centrifuge 5427 R Eppendorf; Wesseling-Berzdorf, Germany 
Rotary microtome Leica RM2255 
Leica Biosystems Nussloch GmbH; Nussloch, 
Germany 
Staining module Leica ST5020 
Leica Biosystems Nussloch GmbH; Nussloch, 
Germany 
Table centrifuge Sprout Mini-Centrifuge Heathrow Scientific LLC; Vernon Hills, IL, USA 
Tissue processor Leica TP1020 
Leica Biosystems Nussloch GmbH; Nussloch, 
Germany 
Vortex Genie 2 Mixer 
OMNILAB-LABORZENTRUM GmbH & Co. KG; 
Bremen, Germany 
Water bath GFL GmbH; Burgwedel, Germany 





Table 8: Used animals 
Animals Strain Sex Source 
Mice C57BL/6JRj Female Janvier; Saint-Berthevin, France 
Mice C57BL6/JOlaHsd Female 



















Table 9: Used software 
Method Software (source) 
Picture analysis ImageJ 1.46r (Wayne Rasband, National 
Institutes of Health; Bethesda, MD, USA) 
Picture acquisition Zen2 (Carl Zeiss Jena GmbH; Jena, Germany) 
Graphic work and Statistics 
GraphPad Prism 5 (GraphPad Software Inc.; 
































2.2.1 In vivo experiments 
All experimental procedures using mice were approved by the State Animal Care and Use Committee 
(Landesdirektion Sachsen, Leipzig, Germany, TVV 56/13) and were carried out in accordance with the 
European Communities Council Directive (86/609/EEC) for the Care and Use of Laboratory Animals. 
All efforts were made to minimize suffering of the animals. Animals were kept at the Centre for 
Experimental Medicine (TEZ) at Fraunhofer Institute for Cell Therapy and Immunology in Leipzig. 
Mice were housed as six animals per cage in a temperature- and light/dark cycle-controlled 
environment (23 °C, 12 h/12 h light/dark, 50 % humidity). They had free access to pelleted standard 
rodent chow and water ad libitum. Animals were acclimatized to the environmental conditions for 
14 days before starting the experiment.  
 
2.2.1.1  Induction of S. enterica-colitis in wild-type animals 
Female C57BL/6JRj mice (10 weeks old; 20-24 g; n=48) were divided into 8 groups. Selected groups 
received a single application of streptomycin at a dose of 20 mg per mouse 24 h prior to infection. To 
prepare a streptomycin solution, 800 mg of streptomycin powder was dissolved in 8 ml of autoclaved 
water to obtain concentration of 100 mg/ml. Mice were administered 200 µl of streptomycin 
solution orally per mouse. Some groups received oral application of autoclaved water only.  
Certain groups of mice were inoculated with 108 colony forming units (cfu) of low-virulent  
S. enterica serovar Enteritidis (SE; 64/03; ade+/his+), using an oral dosing needle. To prepare  
a bacteria solution, a stock solution stored at -150 °C containing 7x109 cfu was thawed and 
centrifuged at 4000 x g, 4 °C for 5 min. The supernatant was discarded and bacteria pellet was 
washed with sterile 3 % NaHCO3-PBS solution. After repeating the centrifugation process, the pellet 
was resuspended in 14 ml of sterile 3 % NaHCO3-PBS solution and stored on ice. For the control of 
viability of used S. enterica stock, part of the prepared bacteria solution was applied on selective 
xylose lysine deoxycholate (XLD) agar plates and incubated for 24 h at 37 °C, 5 % CO2. Afterwards, 
grown colonies were counted. 200 µl (1x108 cfu) of the 3 % NaHCO3-PBS bacteria solution was used 
for the oral inoculation per mouse. Control groups received oral application of the sterile 3 % 
NaHCO3-PBS solution. 
Figure 1 represents a design and course of the experiment.  





Figure 1: General design of the in vivo experiment using WT C57BL/6JRj mice.  
 
2.2.1.2  Induction of S. enterica-colitis in IL-22-deficient animals 
Female C57BL6/JOlaHsd mice (10 weeks old; n=18) and female C57BL6/JOlaHsd IL-22 knock out mice 
(10 weeks old; n=18) were divided into 8 groups. Selected groups received a single application of 
streptomycin at a dose of 20 mg per mouse 24 h prior to infection. Streptomycin solution was 
prepared as described above (2.2.1.1). Mice were administered 200 µl of streptomycin solution orally 
per mouse. Some groups received oral application of autoclaved water only. Certain groups of mice 
were inoculated with 108 cfu of low-virulent S. enterica serovar Enteritidis (SE; 64/03; ade+/his+), 
using an oral dosing needle. Bacteria solution was prepared as described above (2.2.1.1). 200 µl 
(1x108 cfu) of the 3 % NaHCO3-PBS bacteria solution was used for the oral inoculation per mouse. 
Control groups received oral application of the sterile 3 % NaHCO3-PBS solution. 
Figure 2 represent a design and course of the experiment. 
 





Figure 2: General design of the in vivo experiment using IL-22 deficient C57BL6/JOlaHsd mice. 
 
2.2.2 Observation of clinical symptoms of colitis and determination of the clinical score 
Animals were inspected daily for overall appearance. Body weight loss score as well as a score for 
stool consistency were assessed. Scoring systems are shown in tables 10 and 11. The clinical score 

















Table 10: Scoring system for weight loss 




< 2 0.4 
2 – 4 0.8 
4 – 6 1.2 
6 – 8 1.6 
8 – 10 2.0 
10 – 12 2.4 
12 – 14 2.8 
14 – 16 3.2 
16 – 18 3.6 
18 – 20 4.0 
> 20 5 
 
 
Table 11: Scoring system for stool consistency 
Stool consistency Points 
normal 0 
soft, but still formed pellet 0.4 




2.2.3 Dissection and collection of samples 
Starting 24 h post infection (p.i.), blood samples were collected from mice every two weeks. Blood 
was taken from the sublingual vain and transferred into BD Microtainer SSTTM tubes. Serum was 
prepared by 30-60 min incubation at room temperature (RT) followed by centrifugation at 1800 x g 
for 10 min.  Sera were transferred into 0.5 ml tubes and stored at -80 °C until analysis. 
On days 29 and 71 p.i., accordingly, animals were sacrificed using carbon dioxide (following Society of 
Laboratory Animal Science (GV-SOLAS) directions). Afterwards, animals were  




aseptically dissected. Blood samples were collected by cardiac puncture, transferred into BD 
Microtainer SSTTM tubes and processed as described above. Two parts of the most distal and 
proximal colon were taken for histopathological analysis and transferred into 2-ml tubes containing 
Roti® Histofix 4 %, which is a formaldehyde solution fixing the tissue.  
 
2.2.4 Histopathological analysis 
2.2.4.1  Preparation of the colon tissue 
Dehydration of the tissue 
Tissue samples were fixed in Roti®-Histofix 4 % for 24 h at 4 °C and afterwards transferred into 
embedding cassettes. To remove the rests of formalin solution, cassettes were washed with distilled 
water for several times and located in the tissue processor Leica TP 1020. The samples ran through a 
dehydration process, including upgraded series of alcohols, followed by incubation in xylol and 
paraffin type 3. The course of dehydration process is shown in the table 12.  
 
Table 12: Dehydration process of the colon tissue 
Step Chemicals / Reagents Time [min] 
Upgraded series of alcohols 
Ethanol 70 % 60  
Ethanol 70 % 90  
Ethanol 80 % 90  
Ethanol 96 % 60  
Ethanol 96 % 90  
Ethanol 100 % 90  
Ethanol 100 % 90  
Isopropanol 90  
Xylol 90  
Xylol 120  
Paraffin incubation 
Paraffin type 3 120  









Embedding of tissue samples in paraffin blocks 
Embedding station Leica EG1150H was used in order to embed colon tissue samples in paraffin 
blocks. Cassettes containing tissue samples were transferred from the fluid paraffin into  
a heated chamber. Paraffin type 6 was melted at 70 °C and filled into metal forms, where tissue 
samples were aligned afterwards using preheated forceps. Metal forms were moved on  
a cooling plate (-14 °C) to harden the paraffin blocks immediately. After 10 min, the blocks were 
removed from the metal forms.  
 
Production of tissue sections 
Previously prepared paraffin blocks were cooled at a -14 °C plate. Using a rotary microtome Leica 
RM2255, 3-µm thick sections from various regions of the tissue were cut and transferred into water 
bath (50 °C). Sections were mounted on microscope slides and dried on a heating plate (70 °C) in 
order to remove rests of water.  
 
2.2.4.2  Histochemical stainings 
Haematoxylin and eosin (H&E) staining / histopathological score 
The H&E staining was used to get a general overview of pathomorphology in the colon tissue.  
Haematoxylin is a basic dye, which binds to negatively charged regions, e.g. phosphate groups of 
DNA in the cell nucleus. Blue staining is created after change of pH to slightly basic by incubation in 
tap water. The synthetic acidic dye Eosin which binds to plasma proteins and stains them red is used 
afterwards as counterstain. The H&E staining was realized using staining module Leica ST5020 and 
single steps are presented in the table 13. Downgraded series of alcohol allowed removal of paraffin 
and rehydration of tissue sections. After H&E staining procedure, slides were dehydrated in 












Table 13: Process of the H&E staining in Leica ST 5020 staining module 
Step Chemicals / Reagents Time  
Downgraded series of alcohols 
Xylol 5 min 
Xylol 5 min 
Ethanol 100 % 5 min 
Ethanol 90 % 5 min 
Ethanol 80 % 5 min 
Ethanol 70 % 5 min 
Ethanol 50 % 5 min 
high-purity water ≥ 5 min 
H&E staining 
Hem alum solution acid 
acc. to Mayer, filtered 
30 sec 
tap water, flowing 10 min 
Eosin Y solution, filtered 2 min 
Upgraded series of alcohols 
Ethanol 70 % shortly rinse 
Ethanol 90 % shortly rinse 
Ethanol 100 % 30 sec 
Xylol ≥ 1 min 
 
Pictures of stained sections were taken using a slide scanner AxioScan.Z1. Histopathological score 
was determined after stained sections were evaluated by a trained pathologist (Dr. Klaus Weber; 
AnaPath GmbH, Switzerland) with regard to the extent of inflammation and fibrosis, as well as the 
infiltration of immune cells into the tissue. Considered criteria are presented in table 14. The 















Table 14: Histopathological score 
Category Grade Criteria 




4 big, multi-focal infiltration  
5 
Infiltration with a dense presence of 
granulocytes 





big, multi-focal infiltration, affecting up to 50 % 
of the analyzed tissue surface  
5 
dense infiltration of lymphocytes, the whole 
tissue affected  





big, multi-focal infiltration, affecting up to 50 % 
of the analyzed tissue surface  
5 
dense infiltration of macrophages, the whole 
tissue affected  
Fibrosis (mucosa) 
1 focal lesion 
2 several focal lesions 
3 up to 50 % of tissue replaced 
4 up to 80 % of tissue replaced 
5 100 % of tissue replaced 
Fibrosis (submucosa) 
1 focal lesion 
2 several focal lesions 
3 up to 50 % of tissue replaced 
4 up to 80 % of tissue replaced 










Periodic acid-Schiff (PAS) staining and quantification 
PAS reaction was used in order to visualize mucus and mucus-producing goblet cells in the colon 
tissue. Periodic acid is a strong oxidant, which oxidates 1,2-glycoles into aldehydes. These bind 
afterwards to fuchsin sulphurous acids contained in Schiff reagent and stain therefore mucus 
glycoproteins in magenta purple colour. Staining module Leica ST5020 was used to process the 
tissues through downgraded series of alcohols. Afterwards, tissues were transferred into glass 
cuvettes and stained following the steps shown in table 15. After the counterstaining with 
haematoxylin, tissue sections were dehydrated in the staining module and covered with Entellan®. 
Pictures of stained colon sections were taken using the slide scanner AxioScan.Z1 
 
Table 15: Process of the PAS staining in Leica ST 5020 staining module / glass cuvettes 
Step Chemicals / Reagents Time  
Downgraded series of alcohols 
Xylol 5 min 
Xylol 5 min 
Ethanol 100 % 5 min 
Ethanol 90 % 5 min 
Ethanol 80 % 5 min 
Ethanol 70 % 5 min 
Ethanol 50 % 5 min 
high-purity water ≥ 5 min 
PAS reaction 
periodic acid solution 1% 10 min 
tap water 
3 min flowing 
1.5 min standing 
Schiff’s reagent 15 min 
lukewarm tap water 5 min 
Counterstaining 
Hem alum solution acid 
acc. to Mayer, filtered 
1 min 
flowing tap water until water is clean 
tap water 10 min 
Upgraded series of alcohols 
Ethanol 70 % 2 min 
Ethanol 90 % 2 min 
Ethanol 96 % 2 min 
Ethanol 100 % 5 min 
Isopropanol 5 min 
Xylol ≥ 5 min 
 





ImageJ™ software was used to quantify the PAS staining. Software tool “Color deconvolution” 
allowed color dispersion on the tissue section and the violet canal was used for the PAS-stained 
regions. The analysis region was defined by the edge of the outer muscle layer of the colon cross 
section. The intensity of the colored area was related to the total area of the analyzed region. 
 
2.2.4.3  Immunohistochemical (IHC) staining 
For immunofluorescent staining of specific cell markers, i.e. surface markers, transcription factors 
and epithelial markers, an indirect immunohistochemical (IHC) staining was used. 
Tissue sections were subjected to dewaxing and rehydration through downgraded series of alcohols. 
Prior fixation of the colon tissue might cause crosslinking of proteins and therefore antigen masking, 
i.e. the epitope of interest can be no longer detectable for the primary antibody. However, this issue 
can be avoided by practicing antigen retrieval techniques, which were applied depending on the used 
antibody (Table 16): 
a) Heat-induced epitope retrieval (HIER): after the downgraded alcohol series, tissue sections 
were incubated for 25 min in a heated (98 °C) citrate buffer (pH=6) or TRIS-EDTA buffer 
(pH=9). Subsequently, the sections were cooled down for 20 min at RT and then transferred 
to glass cuvettes filled with PBS. 
b) Protease-induced epitope retrieval (PIER): after passing through the downgraded alcohol 
series, tissue sections were transferred into glass cuvettes, which were filled with TRIS-EDTA-
CaCl2 buffer and incubated in a preheated water bath (37 °C ) for 15 min. The slides were 
then incubated with proteinase K at a dilution of 1:1000 for 5 min at  
37 °C. The enzymatic reaction was stopped by rinsing the tissue sections with PBS.  
 
Following the antigen retrieval, individual tissue sections were outlined with wax rings using  
a Dako Pen, which creates a hydrophobic barrier in order to facilitate the application of antibody 
solutions in the subsequent steps. To block non-specific binding, the slides were incubated for 30 min 
at RT in a protein-blocking buffer containing 1% fetal calf serum (FCS). Afterwards, appropriate 
dilution of the primary antibody was applied to the individual sections and incubated in a humid 
chamber for 2 h at RT or overnight at 4 ° C (see Table 16). After washing with PBS-T, slides were 
incubated with an appropriate dilution of the corresponding secondary antibody in a humid 
chamber. Following threefold washing with PBS-T, slides were further incubated with a streptavidine-
Cy3 conjugate (1:1000) for 30 min at RT. After subsequent washing step, stained sections were 




mounted with a 4′,6 diamidin-2-phenylindol (DAPI)-containing mounting medium. DAPI is a 
fluorescent dye, which binds mainly to DNA and stains cell nuclei. 
 
Table 16: Antigen retrieval methods used in immunohistochemical staining 
Antigen Antigen retrieval method 
Incubation time with 
a primary antibody 
CD3 HIER, Tris-EDTA buffer (pH=9) 2 h 
Claudin-1 HIER, Citrate buffer (pH=6) 2 h 
IFN- PIER overnight 
IgA HIER, Citrate buffer (pH=6) 2 h 
IL-22 HIER, Citrate buffer (pH=6) 2 h 
RORt PIER 2 h 
 
Pictures of stained colon sections were taken and digitized using an image scanner Axio.Scan™ Z1. 
Signals for Cy3 and DAPI were measured in a previously defined region of interest (ROI) applying 
previously saved greyscale limits. By excitation of Cy3 within a wavelength range of 526-562 nm and 
measurement of the emission at 561 nm, the investigated cell markers could be visualized. The 
excitation of DAPI at 333-387 nm and subsequent measurement of the emission at 465 nm enabled 
the localization of the cell nuclei. The quantification of the individual cell markers was carried out via 
image analysis using the program ImageJ™ 1.46r. For each treatment group, two sections per animal 
were analyzed. The analysis area was defined and included the area within the outer muscle layer of 
the colon. Unspecific coloured regions in the intestinal lumen were excluded from the analysis 
region. The border areas for the intensity of the channels were determined for each staining in a 
preliminary experiment. The software decomposed the channels in red, yellow and blue colours. 
Therefore, Cy3 could be analyzed by red and DAPI by blue channel. For both channels, the same area 
of analysis was determined and the intensity was measured. Expression of the markers was 
presented as Cy3-positive area relative to the DAPI-positive area [%].  
 
2.2.5 Determination of S. enterica load in faecal pellets 
To analyse colonization of the colon with S. enterica, faecal samples were collected every two weeks, 
starting 24 h p.i., immediately transferred into cold sterile PBS and stored on ice. The faecal pellets 
were processed under a clean bench: crushed with a sterile pipette tip and  
vigorously vortexed to obtain a homogenous solution. Afterwards, appropriate dilutions of samples 
were prepared and 100 µl of each was applied on selective XLD agar plates and incubated for 24 h at 




37 °C, 5 % CO2. The cfu of S. enterica per pellet were determined by counting characteristic black 
colonies, which appear black due to the metabolism of sodium thiosulfate into hydrogen sulfate by 
S. enterica. 
 
2.2.6 Analysis of S. enterica-specific antibodies in serum 
To investigate specific antibodies against S. enterica present in serum of mice, an enzyme-linked 
immunosorbent assay (ELISA) was performed. First, 96-well plates were coated with S. enterica 
antigens. Therefore, S. enterica antigen solution prepared previously within the working group was 
diluted to a concentration of 1 μg/ml and 100 µl of the solution was applied to each well. The plates 
were sealed and stored overnight at 4 °C. Subsequently, the plates were washed twice with 300 μl of 
PBS-T. To block unspecific antibody binding, 0.5 % casein block buffer was added to each well, 
incubated for 1 h in a humid chamber at RT and washed three times with 300 µl of PBS-T. Serum 
samples were diluted 1:200 in PBS and 100 µl of each dilution was applied into an appropriate well. 
As a buffer control, 100 µl of PBS was used. The specificity of the antibody binding was checked by a 
conjugate control (100 µl PBS + detection antibody), without serum. Plates were sealed and 
incubated for 2 h in a humid chamber at RT. To remove non-specifically bound antibodies, plates 
were washed three times with 300 µl of PBS-T. Next, 100 µl of diluted immunoglobulin-specific 
antibody (IgA, IgM, IgG1 or IgG2c) conjugated with horseradish peroxidase were applied to each well 
(Tale 6). PBS-T served as a buffer control. Following application, plates were sealed and incubated for 
1 h in a humid chamber at RT, protected from light. Subsequently, the washing step was repeated 
and 100 μl of 3,3', 5,5'-tetramethylbenzidine (TMB) solution per well was applied for detection. 
During light-protected incubation for 5 min in a humid chamber at RT, the horseradish peroxidase 
oxidized the chromogenic TMB in the presence of hydrogen peroxide. Reaction was stopped by 
addition of 100 μl of 0.5 M sulfuric acid to each well. The amount of oxidized substrate was 
quantified by measuring the optical density (OD) at 450 nm using a conventional microplate reader 
Tecan Safire2. The measured OD values of the buffer controls were subtracted from the OD values of 
the samples. Since the amount of oxidized substrate depends on the amount of horseradish 
peroxidase-conjugated antibody, the S.enterica-specific antibodies present in the blood serum could 
be qualitatively compared. 
 
 




2.2.7 Statistical analysis 
All data were analyzed using GraphPad™ Prism 6. Clinical data are presented as mean or  
median ±SD. Data for histological analysis and S. enterica load in feces are presented as individual 
data points. Significant differences between data sets were estimated by Kruskal-Wallis one-way 
ANOVA (if normally distributed) or by One-way ANOVA on Ranks (if the normality test failed) 
followed by Dunn’s multiple comparison test. Differences between data sets for clinical score and 
specific antibodies in serum were analyzed by Two-way ANOVA followed by Holm-Sidak’s multiple 
comparison test. Values were considered significantly different if P< 0.05, with P< 0.01, P< 0.001 or 




























3.1 Oral infection with S. enterica induces clinical symptoms of colitis, which are 
exacerbated by streptomycin pretreatment in the acute phase of infection 
To establish a mouse model of chronic bacterial infection, mice were inoculated with S. enterica with 
or without a single dose of streptomycin treatment 24 h prior to infection. Clinical symptoms, 
including body weight change and stool consistency, were examined daily over  
a period of 10 weeks. A clinical score was determined for each mouse as the mean of the scores for 
body weight change and stool consistency. Figure 3 shows the course of the clinical score over the 






Figure 3: Course of the clinical score in the mouse model of chronic S. enterica infection. Chronic infection was induced in 
C57BL/6 mice by oral inoculation with S. enterica (S.e.) without (a) or with (b) a single dose of streptomycin (Strep.; 
20 mg/mouse) 24 h prior to infection. Animals treated with PBS were used as negative control. The clinical score was 
determined daily and is shown as mean ± SD (a-b) or mean (c) for n=12 animals (0-29 days) or n=6 (30-70 days) per group. 








Starting from day 9, infected mice showed loss of body weight as well as persisting diarrhea. In 
comparison to the PBS control group, infected animals without antibiotic pretreatment showed 
significantly elevated (P<0.05) clinical symptoms at day 10 p.i. (Figure 3 a). In mice pretreated with 
streptomycin, a significantly (P<0.0001) elevated clinical score was already observed on day 3 p.i. 
(Figure 3 b). In both cases, clinical symptoms persisted until the end of the experiment. In 
comparison to S. enterica infection alone, streptomycin pretreatment caused a significant (P<0.05) 
increase of the clinical score as soon as 2 days p.i. This effect was observable from day 3 to 6 p.i. and 
even more pronounced from day 12 to day 18 p.i. (P<0.001). After day 18, clinical symptoms in both 
groups settled at approximately the same level (Figure 3 c).  
 
3.1.1 IL-22-deficiency causes exacerbation of clinical symptoms in the early phase of 
infection 
To investigate whether IL-22 significantly contributes to the immune response against S. enterica 
infection, the model of chronic infection introduced above was used. Mice were infected with 
S. enterica and a single dose of streptomycin was administered 24 h prior to bacterial inoculation. 
Clinical symptoms, including body-weight change and stool consistency were assessed daily for 
4 weeks. Based on these parameters, the clinical score for each mouse was determined. Figure 4 







Figure 4: Course of the clinical score over 4 weeks post infection with S. enterica. Chronic infection was induced in wild-
type (WT) or IL-22-deficient (IL-22-/-) C57BL/6 mice by oral inoculation with S. enterica (S.e.) with a single dose of 
streptomycin (Strep.; 20 mg/mouse) 24 h prior to infection. Animals treated with PBS were used as negative control. The 
clinical score was assessed daily and is shown as mean ± SD for WT Strep. + PBS n=6, WT Strep. + S.e. n=11, IL-22-/- Strep. + 
PBS n=6, IL-22-/- Strep. + S.e. n=12  animals (a-c). Statistics: Two-way ANOVA followed by Holm-Sidak’s multiple comparisons 





Starting at day 15 p.i., an increase in the clinical score in WT animals was observed, whereas  
IL-22-defficient mice showed significant clinical symptoms already at day 12 p.i. (Figure 4 a, b). Both 
groups maintained a significantly elevated clinical score until the end of experiment. In direct 
comparison, IL-22-defficient animals developed clinical symptoms significantly faster than WT 
animals, and the clinical score stayed on a significantly higher level up to day 17 p.i. However, the 
difference between the groups was less pronounced in the later phase of the experiment (Figure 4 c).  
 
  
3.2 Histopathological aberrations in the colon tissue caused by oral infection with S. 
enterica are exacerbated by antibiotic pretreatment 
To investigate the pathohistlogical changes in the colon tissue caused by infection with S. enterica, a 
histopathological score based on H&E-stained cross sections of the proximal and distal colon was 
assessed by a trained pathologist at two time points of the experiment (4 weeks p.i. and 10 weeks 
p.i.). The H&E staining allowed investigation of general structural aberrations as well as functional 
changes in the tissue. The histopathological score is a crucial parameter for evaluating tissue 
degeneration and inflammation and considers the extent of fibrosis in mucosa and submucosa, the 
infiltration of lymphocytes, granulocytes and macrophages, as well as the formation of edema.  
The histological analysis revealed moderate inflammatory infiltration affecting the mucosa and 
submucosa, which was very rich in cells and consisted mainly of lymphocytes and granulocytes 
(Figure 5 a; S.e. 4 weeks p.i., S.e. 10 weeks p.i., Strep. + S.e. 4 weeks p.i., Strep. + S.e. 10 weeks p.i.). 
Fibrocytes and fibroblasts forming fibrotic lesions as well as some cases of perforation were also 
noticeable in the colon tissue of streptomycin-pretreated mice (Figure 5 a; Strep.+ S.e. 10 weeks p.i. 
proximal and distal). In summary, routine sections revealed lesions that were mainly characterized by 
an inflammatory infiltrate affecting the mucosa and submucosa. Furthermore, the infiltrate formed a 
cuneiform shape that was often related to a perforating lesion. The morphological character was 











Figure 5: Histopathological changes assessed 4 and 10 weeks after infection with S. enterica. Chronic infection was 
induced in C57BL/6 mice by oral inoculation with S. enterica (S.e.) without (a) or with (b) a single dose of streptomycin 
(Strep.; 20 mg/mouse) 24 h prior to infection. Animals treated with PBS were used as negative control. The 
histopathological score was evaluated based on H&E-stained cross sections (a) of the proximal (b, c, f) and distal (d, e, g) 
colon for 6 animals per group, Strep. + S.e. 10 w n=5 animals; scale bars: 200 µm. The median of individual data points is 
indicated. Statistics: One-way ANOVA followed by Dunn’s multiple comparisons test. *P<0.05; **P<0.01; ***P<0.001. 
 
If compared to the PBS control group, a significantly (P<0.001) elevated histopathological score was 
observed for the tissue from the proximal colon of mice infected with S. enterica without 
pretreatment only at 10 weeks p.i. (Figure 5 b). However, in the proximal colon of streptomycin-
pretreated mice, significant (P<0.01) symptoms of tissue inflammation were already observed 
4 weeks p.i. (P<0.01) but also at 10 weeks p.i. (Figure 5 c). Histopathological findings in the distal 
colon were similar, but in contrast to the proximal colon significant (P<0.05) pathological changes in 
S. enterica-infected mice were already observed at 4 weeks p.i. (Figure 5 d). Pretreatment with 
streptomycin resulted in a significantly exacerbated histopathological score at 4 weeks (P<0.01) and 
10 weeks (P<0.05) p.i. (Figure 5 e). Direct comparison of groups with and without antibiotic 
pretreatment showed that streptomycin caused a significant (P<0.01) increase in the severity of 
tissue inflammation in both the proximal and distal colon at 4 weeks p.i. (Figures 5 f and 5 g). 
However, at 10 weeks p.i. this difference was no longer present since mice without pretreatment 
revealed symptoms of similar severity as found in streptomycin-treated animals at this period of 
infection.  
 
3.2.1 Histological aberrations caused by oral infection with S. enterica are not dependent 
on presence of IL-22 
To investigate pathohistological changes in the colon tissue caused by infection with S. enterica and a 
possible contribution of IL-22 a histopathological score based on H&E-stained cross-sections of the 
proximal and distal colon was assessed by a trained pathologist 4 weeks p.i. Figure 10 shows H&E 
















Figure 6: Histopathological changes assessed 4 weeks post infection with S. enterica. Chronic infection was induced in 
wild-type (WT) or IL-22-deficient (IL-22-/-) C57BL/6 mice by oral inoculation with S. enterica (S.e.) and administration of a 
single dose of streptomycin (Strep.; 20 mg/mouse) 24 h prior to infection. The histopathological score was evaluated based 
on H&E-stained cross-sections (a) of the proximal (b) and distal (c) colon for groups: WT Strep. + PBS, IL-22-/- Strep. + PBS 
n=6, WT Strep. + S.e. n=12, IL-22-/- Strep. + S.e. n=9. Direct comparison of the histopathological scores between WT and IL-
22-/- mice is shown (d). The median of individual data points is indicated. Statistics: One-way ANOVA followed by Dunn’s 
multiple comparisons test. **P<0.01; ***P<0.001. 
 
 
If compared to healthy control animals, a significantly elevated histopathological score could be 
observed in the proximal colon of both WT and IL-22-deficient mice (Figure 6 b). In addition, WT mice 
showed significant morphological changes in the tissue of the distal colon, whereas these changes 





between WT and IL-22-deficient mice revealed no significant difference, neither in the proximal nor 
in the distal colon (Figure 6 d). 
 
3.2.2 IL-22 deficiency causes increased loss of goblet cells in the proximal colon of 
S. enterica-infected mice 
Goblet cells play a crucial role in the defense against pathogenic infection of the gut by producing 
mucus, thus creating a barrier that is hard to penetrate by invading bacteria. Loss of goblet cells is a 
typical symptom of the inflammatory reaction in the colon tissue, as observed in patients with IBD. 
Therefore, cross-sections of the colon from WT and IL-22-deficient mice were stained with PAS, 
which allows visualization of mucus and mucus-producing cells as purple-stained regions. Figure 5 
shows microphotographs of PAS-stained cross-sections (Figure 7 a) and quantification of PAS-positive 






















Figure 7: Quantification of mucus and mucus-producing cells in the colon of S. enterica-infected mice. Chronic infection 
was induced in wild-type (WT) or IL-22-deficient (IL-22-/-) C57BL/6 mice by oral inoculation with S. enterica (S.e.) with a 
single dose of streptomycin (Strep.; 20 mg/mouse) 24 h prior to infection. The areas containing mucus or mucus-producing 
cells were quantified based on PAS-stained cross sections (a) of the proximal (b) and distal (c) colon for groups: WT Strep. + 
PBS, IL-22-/- Strep. + PBS n=6, WT Strep. + S.e. n=12, IL-22-/- Strep. + S.e. n=9. Direct comparison of the quantification of 
mucus production in the colon between WT and IL-22-deficient mice is shown (d). The median of individual data points is 
indicated. Statistics: One-way ANOVA followed by Dunn’s multiple comparisons test. *P<0.05; **P<0.01; ***P<0.001.  
 
 
Significantly (P<0.05) expanded areas containing mucus were observed in the proximal colon of WT 
animals in comparison to the healthy control group. At the same time point, an opposite tendency 
was found for IL-22-deficient animals, which showed a significantly (P<0.001) reduced amount of 
mucus or mucus-producing cells (Figure 7 b). In the distal colon, IL-22-deficient mice showed a 





However, there were no observable differences between healthy and S.e.-infected WT animals 
(Figure 7 c). In direct comparison, IL-22-deficient animals showed a significantly (P<0.05) reduced 
production of mucus in the proximal tissue, whereas no detectable differences were observed for the 
distal part of the gut (Figure 7 d).  
 
 
3.3 Streptomycin alters the course of S. enterica colonization in the gut 
To analyze colonization of the gut after inoculation with S. enterica, fecal pellets were collected every 
2 weeks starting 24 h p.i. Samples were homogenized and plated onto XLD agar to differentiate 
S. enterica colonies from other bacteria present in the gut. The cfu per fecal pellet were determined 
by counting characteristic colonies formed on XLD agar, which appear black-colored due to the 
metabolism of sodium thiosulfate into hydrogen sulfate by S. enterica. Figure 8 shows the S. enterica 







Figure 8: Number of S. enterica cfu per fecal pellet assessed over 10 weeks post infection. Chronic infection was induced 
in C57BL/6 mice by oral inoculation with S. enterica (S.e.) without (g) or with (h) a single dose of streptomycin (Strep.; 
20 mg/mouse) 24 h prior to infection. Fecal samples were collected from each mouse every 2nd week, homogenized and 
applied on XLD agar. After 24 h, S. enterica colonies were counted and are displayed as cfu/pellet (a-f). Bacteria load 
determined throughout the course of the experiment in infected mice is shown (g, h). The median of individual data points 
is indicated. Statistics: Mann-Whitney test (a-f) and One-way ANOVA followed by Dunn’s multiple comparisons test (g, h). 
Number of animals per group: n=3-12. *P<0.05; **P<0.01; ***P<0.001; ****P<0.0001. 
 
 
Already at 24 h p.i., a significantly (P<0.0001) higher load of the pathogen could be detected in mice 
pretreated with streptomycin (Figure 8 a). At 2 weeks p.i., there was still a significant (P<0.001) 





colon of pretreated animals remained at the same high level (range 107 cfu), whereas the bacterial 
load in the group without streptomycin pretreatment had slightly increased from range 102 up to 105 
cfu (Figure 6 b). This trend continued at later time points, where bacterial loads of both groups were 
found at similar high levels, i.e. 106-107 cfu. Observed reduced cfu level in streptomycin-pretreated 
group 6 weeks p.i. was most likely due to limited number of samples (Figures 8 c-f). This observation 
was consistent with the development of the clinical scores in both groups, which also converged at 
later time points (Figure 3 c). Analysis of the bacterial burden throughout the course of the 
experiment revealed that inoculation with S. enterica only caused an increase in colonization of the 
gut over time (Figure 8 g). Streptomycin pretreatment caused immediate raise of the bacterial load, 
which remained on a similar high level until week 10 p.i. (Figure 8 h). 
 
3.3.1 Mice lacking IL-22 are more susceptible to the colonization with S. enterica 
To analyze colonization of the gut with administered S. enterica, stool samples were collected at 
24 h, 2 weeks and 4 weeks p.i. Fecal pellets were homogenized and plated on XLD agar. After 24 h of 
incubation at 37 °C, the cfu numbers per each pellet were determined by counting characteristic 








Figure 9: S. enterica cfu in fecal pellets from mice infected with S. enterica. Chronic infection was induced in wild-type 
(WT) or IL-22-deficient (IL-22-/-) C57BL/6 mice by oral inoculation with S. enterica (S.e.) and administration of a single dose 
of streptomycin (Strep.; 20 mg/mouse) 24 h prior to infection. Fecal pellets were collected from mice at 24 h, 2 weeks and 4 
weeks p.i., homogenized and plated onto XLD-agar. After 24 h, S. enterica colonies were counted and are displayed as 
cfu/pellet (a-c). Bacteria load determined throughout the course of the experiment in infected WT (d) and IL-22-deficient 
(e) mice is shown. The median of individual data points is indicated. Statistics: Mann-Whitney test (a-c) and One-way 




Already 24 h p.i., about half of the IL-22-deficient group manifested a significant (P<0.01) load of S. 
enterica, whereas no bacterial load was observed in WT animals at this time point (Figure 9 a). 2 
weeks p.i., the average number of cfu was still significantly higher in IL-22-deficient mice (Figure 9 b), 
whereas this difference was no more observable 4 weeks p.i. (Figure 9 c). Analysis of the S. enterica 
load throughout the course of the experiment showed that colonization of the gut increased over 
time in WT mice and was significantly (P<0.001) higher 4 weeks p.i. (Figure 9 d). In contrast, bacterial 
colonization in IL-22-deficient mice occurred rapidly and remained on a similar high level until the 





3.4 Streptomycin affects the local immune response in the colon tissue of  
S. enterica-infected mice 
To further investigate the local immune response to S. enterica invasion in the colon tissue, cross-
sections of the distal colon were analyzed by immunofluorescence staining. The analysis focused on 
exemplary markers relevant for the mucosal immune response in the gut tissue, i.e. cluster of 
differentiation (CD) 3, Interferon-gamma (IFN-), IL-22 and secretory immunoglobulin A (sIgA).  
 
3.1.1. CD3 
CD3 is a basic marker of T cells expressed on their surface. Staining of the CD3-positive (CD3+) cells 
provided an overview of the infiltration of T cells into the inflamed tissue, indicating the role of these 
cells in the immune reaction against S. enterica infection. Figure 10 shows microphotographs of the 
CD3-stained cross-sections (Figure 10 a), as well as quantification of CD3 expression in stained cross-






Figure 10: Analysis of CD3 expression in the colon tissue of mice infected with S. enterica. Chronic infection was induced 
in C57BL/6 mice by oral inoculation with S. enterica (S.e.) without or with administration of a single dose of streptomycin 
(Strep.; 20 mg/mouse) 24 h prior to infection. Animals treated with PBS were used as negative control. Cross-sections of the 
distal colon were stained for the T cell marker CD3; scale bars: 200 µm (a). Stained cross-sections (2 sections/mouse) were 
digitized by means of a slide scanner (AxioScan.Z1, Zeiss). Expression was quantified using the software program ImageJ® 
and is shown as marker-positive area relative to the DAPI-positive area (b-d). The median of individual data points is 
indicated. Statistics: One-way ANOVA followed by Dunn’s multiple comparisons test. Number of animals per group: n=6, 
Strep. + S.e. 10 w n=5 animals. **P<0.01; ***P<0.001; ****P<0.0001. 
 
 
In comparison to the PBS control group the numbers of infiltrating T cells were significantly higher in 
the colon tissue of S. enterica-infected mice at 4 weeks p.i. (P<0.001) and 10 weeks p.i. (P<0.01) 
(Figure 10 b). In mice pretreated with streptomycin, differences to the healthy control group were 





significantly (P<0.01) higher expression of CD3 in the colon tissue than mice without antibiotic 
pretreatment at 10 weeks p.i. (Figure 10 d). 
 
3.4.1 IFN- 
IFN-, a cytokine produced by NK cells and activated T cells, plays an important role in the host 
response to intracellular pathogens, such as S. enterica. Analysis of IFN- expression therefore 
provided further insight into the T-cell-mediated immune response to S. enterica infection in the gut. 
Figure 11 shows microphotographs of the IFN--stained cross-sections (Figure 11 a), and the 









Figure 11: Analysis of IFN- expression in the colon tissue of mice infected with S. enterica. Chronic infection was induced 
in C57BL/6 mice by oral inoculation with S. enterica (S.e.) without or with administration of a single dose of streptomycin 
(Strep.; 20 mg/mouse) 24 h prior to infection. Animals treated with PBS were used as negative control. Cross-sections of the 
distal colon were stained for the inflammatory marker IFN-; scale bars: 200 µm (a). Stained cross-sections (2 
sections/mouse) were digitized by means of a slide scanner (AxioScan.Z1, Zeiss). Expression was quantified using the 
software program ImageJ® and is shown as marker-positive area relative to the DAPI-positive area (b-d). The median of 
individual data points is indicated. Statistics: One-way ANOVA followed by Dunn’s multiple comparisons test. Number of 
animals per group =6, Strep. + S.e. 10 w n=5 animals. *P< 0.5;**P< 0.01; ***P< 0.001. 
 
 
Consistent with the analysis of CD3 expression, a significantly (P<0.001) higher level of IFN- 





level decreased again until 10 weeks p.i. (Figure 11 b). In animals pretreated with streptomycin, 
expression of IFN- was significantly (P<0.01) elevated at both 4 weeks p.i. and 10 weeks p.i. (Figure 
11 c). In direct comparison, antibiotic pretreatment resulted in an increased expression of IFN- in 
the colon tissue of infected animals at both analytical time points 4 weeks p.i. (P<0.05) and 10 weeks 
p.i. (P<0.01) (Figure 11 d).  
 
3.4.2 IL-22 
IL-22, produced by different cells of the innate and adaptive immune system (i.e. ILC3, Th17, Th22 
cells) contributes to tissue regeneration and plays an important role in the host defense at barrier 
surfaces. Therefore, the quantification of IL-22 expression in the colon tissue provided important 
information on its role in the mucosal immune response against S. enterica. Figure 12 shows 
microphotographs of the IL-22-stained cross-sections (Figure 12 a), as well as the quantification of IL-







Figure 12: Analysis of IL-22 expression in the colon tissue of mice infected with S. enterica. Chronic infection was induced 
in C57BL/6 mice by oral inoculation with S. enterica (S.e.) without or with administration of a single dose of streptomycin 
(Strep.; 20 mg/mouse) 24 h prior to infection. Animals treated with PBS were used as negative control. Cross-sections of the 
distal colon were stained for IL-22; scale bars: 200 µm (a). Stained cross-sections (2 sections/mouse) were digitized by 
means of a slide scanner (AxioScan.Z1, Zeiss). Expression was quantified using the software program ImageJ® and is shown 
as marker-positive area relative to the DAPI-positive area (b-d). The median of individual data points is indicated. Statistics: 
One-way ANOVA followed by Dunn’s multiple comparisons test. Number of animals per group = 6, Strep. + S.e. 10 w n=5 
animals. *P< 0.5;**P< 0.01. 
 
 
If compared to the PBS control group, the number of IL-22-expressing cells was not elevated in the 
colon tissue of S. enterica-infected animals at 4 weeks p.i. However, a significant increase of IL-22-





pretreated animals, a significant increase of IL-22-positive cells was observed already 4 weeks p.i. 
(P<0.01) that lasted until the end of the experiment (P<0.01) (Figure 12 c). If compared directly, 
antibiotic-pretreated S.e.-infected mice showed significantly higher (P<0.05) expression of IL-22 
shown as IL-22-positive cells in the colon tissue than animals only infected with S.e. without 
streptomycin pretreatment at 4 weeks p.i., whereas this difference was no more detectable at 10 
weeks p.i. (Figure 12 d).  
 
3.4.3 Secretory IgA  
sIgA is a vital component of the innate immune system, which plays a critical role in the mucosal 
immune responses. sIgA is secreted into the mucus and gut lumen and is an important marker for the 
mucosal immune response. Figure 13 shows microphotographs of the IgA-stained cross-sections 






Figure 13: Analysis of IgA expression in the colon tissue of mice infected with S. enterica. Chronic infection was induced in 
C57BL/6 mice by oral inoculation with S. enterica (S.e.) without or with administration of a single dose of streptomycin 
(Strep.; 20 mg/mouse) 24 h prior to infection. Animals treated with PBS were used as negative control. Cross-sections of the 
distal colon were stained for immunoglobulin A; scale bars: 200 µm (a). Stained cross-sections (2 sections/mouse) were 
digitized by means of a slide scanner (AxioScan.Z1, Zeiss). Expression was quantified using the software program ImageJ® 
and is shown as marker-positive area relative to the DAPI-positive area (b-d). The median of individual data points is 
indicated. Statistics: One-way ANOVA followed by Dunn’s multiple comparisons test. Number of animals per group = 6, 
Strep. + S.e. 10 w n=5 animals. ***P< 0.001, ****P< 0.0001. 
 
 
No significant differences in the expression of IgA were observed between healthy and infected mice 
irrespective of antibiotic pretreatment at 4 or 10 weeks p.i. (Figures 13 b-c). However, if compared to 





with antibiotic pretreatment was significantly reduced at both 4 weeks p.i. (P<0.0001) and 10 weeks 
p.i. (P<0.001) (Figure 13 d). 
 
 
3.5 IL-22 deficiency impairs the intestinal epithelial barrier of the mice infected 
with S. enterica. 
Investigation of the S. enterica-induced gut inflammation revealed contribution of IL-22 to the 
intestinal immune reaction against the pathogen. Therefore, additional aim of this study was to 
analyze the role of IL-22 in the development of chronic inflammation in the gut tissue in the model of 
bacteria-induced colitis.To investigate whether IL-22 depletion alters the local immune response 
against S. enterica infection in the gut, cross sections of the distal colon were stained using 
immunofluorescence. The analysis focused on exemplary markers relevant for the immune and 
function of epithelial barrier in the gut, i.e. CD3, RORt, and Claudin-1. 
 
3.5.1 CD3 
Staining of the CD3+ cells provided an insight into T cell number and location in the inflamed colon 
tissue. Thus, it allowed preliminary analysis of T cell contribution to the immune reaction against S. 
enterica, as well as the influence of IL-22-deficiency on the T cell response in the gut. Figure 14 shows 
microphotographs of CD3-stained cross-sections (Figure 14 a) and quantification of CD3 expression in 







Figure 14: Analysis of CD3 expression in the colon tissue of mice infected with S. enterica. Chronic infection was induced 
in wild-type (WT) or IL-22-deficient (IL-22-/-) C57BL/6 mice by oral inoculation with S. enterica (S.e.) with administration of a 
single dose of streptomycin (Strep.; 20 mg/mouse) 24 h prior to infection. Animals treated with PBS were used as negative 
control. Cross-sections of the proximal (b) and distal (c) colon were stained for the T cell marker CD3; scale bars: 200 µm (a). 
Stained cross-sections (2 sections/mouse) were digitized by means of a slide scanner (AxioScan.Z.1, Zeiss). Expression was 
quantified using the software program ImageJ® and is shown as marker-positive area relative to the DAPI-positive area (b-d) 
The median of individual data points is indicated. Statistics: One-way ANOVA followed by Dunn’s multiple comparisons test. 
Number of animals per group: WT Strep. + PBS, IL-22-/- Strep. + PBS n=6, WT Strep. + S.e. n=12, IL-22-/- Strep. + S.e. n=9. 








Four weeks post infection with S. enterica, WT animals showed significantly (P<0.01) elevated  
expression of CD3 in the analyzed cross-sections from both proximal and distal part of the colon if 
compared to the healthy control animals. This effect was even more pronounced (P<0.001) in the IL-
22-deficient group (Figure 14 b-c). However, in direct comparison, there were no significant 
differences in the number of infiltrating T cells caused between WT and IL-22-deficient mice (Figure 
14 d).  
3.5.2 RORt 
Retinoic-acid related orphan receptor gamma t (RORt) is one of the isoforms of the ROR 
transcription factors and is expressed by various Th cells, e.g. Th17 and Th22 cells, which express IL-
22 as well. Analysis of RORt-positive (RORt+) cells provided insight whether IL-22-associated T cells 
were involved in the immune response against S. enterica infection in the colon tissue. Figure 15 
shows microphotographs of RORt-stained cross-sections (Figure 15 a) and the quantification of 








Figure 15: Analysis of RORt expression in the colon tissue of mice infected with S. enterica. Chronic infection was 
induced in wild-type (WT) or IL-22-deficient (IL-22-/-) C57BL/6 mice by oral inoculation with S. enterica (S.e.) with 
administration of a single dose of streptomycin (Strep.; 20 mg/mouse) 24 h prior to infection. Animals treated with PBS 
were used as negative control. Cross-sections of the proximal (b) and distal (c) colon were stained for the transcription 
factor RORt; scale bars: 200 µm (a). Stained cross-sections (2 sections/mouse) were digitized by means of a slide scanner 
(AxioScan.Z.1, Zeiss). Expression was quantified using the software program ImageJ® and is shown as marker-positive area 
relative to the DAPI-positive area (b-d) The median of individual data points is indicated.  Statistics: One-way ANOVA 
followed by Dunn’s multiple comparisons test. Number of animals per group: WT Strep. + PBS, IL-22-/- Strep. + PBS n=6, WT 






If compared to the PBS control group, a significantly (P<0.001) increased expression of RORt was 
determined in the proximal colon tissue of WT animals at the 4 weeks p.i. This observation was even 
more pronounced (P<0.0001) in the IL-22-deficient group (Figure 15 b). The relation was similar in 
the distal part of the colon, where infiltration of RORt-producing cells into the intestinal tissue was 
significantly higher (P<0.01) in infected WT mice and even more pronounced in infected IL-22-
deficient mice (Figure 15 c). When the WT and IL-22-/- groups were directly compared at 4 weeks p.i., 
IL-22-/- mice revealed somewhat higher amounts of infiltrating RORt+, however this difference was 
only weakly significant (P<0.05) and occurred only in the proximal, but not in the distal part of the 
colon (Figure 15 d). 
3.5.3 Claudin-1 
Intestinal barrier is a crucial mechanism, protecting from invasion of pathogens into the mucosa 
during infection. Claudin-1 is a tight-junction protein and an important component of the 
connections between cells in the gut epithelium. Figure 16 shows microphotographs of  
Claudin-1-stained cross-sections (Figure 16 a) and the quantification of Claudin-1 expression in 







Figure 16: Analysis of Claudin-1 expression in the colon tissue of mice infected with S. enterica: Chronic infection was 
induced in wild-type (WT) or IL-22-deficient (IL-22-/-) C57BL/6 mice by oral inoculation with S. enterica (S.e.) with 
administration of a single dose of streptomycin (Strep.; 20 mg/mouse) 24 h prior to infection. Animals treated with PBS 
were used as negative control. Cross-sections of the proximal (b) and distal (c) colon were stained for the TJ protein 
Claudin-1; scale bars: 200 µm (a). Stained cross-sections (2 sections/mouse) were digitized by means of a slide scanner 
(AxioScan.Z.1, Zeiss). Expression was quantified using the software program ImageJ® and is shown as marker-positive area 
relative to the DAPI-positive area (b-d) The median of individual data points is indicated. Statistics: One-way ANOVA 
followed by Dunn’s multiple comparisons test. Number of animals per group: WT Strep. + PBS, IL-22-/- Strep. + PBS n=6, WT 






WT mice infected with S. enterica showed significantly (P<0.001) higher expression of Claudin-1 in 
the proximal part of the colon in comparison to the PBS control group 4 weeks p.i. (Figure 16 b). At 
the same time point, expression of Claudin-1 in the proximal colon of  
IL-22-deficient mice stayed at the same level as in untreated animals. Analysis of Claudin-1 
expression in the distal part of the colon did not show any significant differences caused by infection 
with the pathogen (Figure 16 c). In direct comparison, following S. enterica infection IL-22-defficient 
mice had significantly (P<.0.05) lower expression of Claudin-1 in the proximal part of the colon than 
WT animals. There were no differences observed in the distal colon (Figure 16 d).  
 
3.6 The systemic S. enterica-specific antibody response is temporary increased by 
pretreatment with streptomycin 
Starting 24 h p.i., peripheral blood was collected every 2 weeks and serum was analyzed by ELISA for 
S. enterica-specific antibodies (IgA, IgM, IgG1, and IgG2c). The obtained OD values proportionally 
related to the concentration of the analyzed antibodies and thus allowed the comparison of antibody 
levels in the serum of S. enterica-infected animals. IgA and IgM are markers of acute infection, 
whereas IgG is detectable in blood for an extended period after infection. Figure 17 shows the course 






Figure 17: Course of the systemic antibody response analyzed in sera of mice infected with S. enterica. Chronic infection 
was induced in C57BL/6 mice by oral inoculation with S. enterica (S.e.) without or with administration of a single dose of 
streptomycin (Strep.; 20 mg/mouse) 24 h prior to infection. Animals treated with PBS were used as negative control. Blood 
was collected from mice every two weeks and serum was prepared and stored at -80 °C until analysis. Titers of the S. 
enterica-specific antibodies IgA (a-c), IgM (d-f), IgG1 (g-i), and IgG2c (j-l) were determined by ELISA. The OD values were 
measured at a wavelength of 450 nm using a microplate reader (Safire2, Tecan) and are shown as mean ± SD. Statistics: 
Two-way ANOVA followed by Holm-Sidak’s multiple comparisons test. Number of animals per group: n=12 (0-4 w) or n=6 
(6-10 w). *P<0.05; **P<0.01; ***P<0.001; ****P<0.0001. 
 
 
A significantly (P<0.001) higher concentration of IgA was detected in infected mice at  
4 weeks p.i. (Figure 17 a). At the same time point, there was also a significantly elevated (P<0.0001) 
level of IgA in the serum of streptomycin-pretreated mice (Figure 17 b). In direct comparison, a 
significantly (P<0.0001) higher pathogen-specific IgA response could be observed after antibiotic 
pretreatment at 4 weeks p.i. (Figure 17 c). Similar to IgA, specific IgM antibodies were significantly 





pretreated mice, a significantly (P<0.01) higher specific IgM serum level was already detected at 2 
weeks p.i. and lasted until 6 weeks p.i. (P<0.0001) (Figure 17 e). Thus, streptomycin pretreatment 
caused an earlier specific IgM response (Figure 17 f). The amount of S. enterica-specific IgG 
antibodies was measured to investigate the course of the immune response in a later phase of 
infection. The titers of IgG2c and IgG1 isotypes served as markers for Th1 and Th2 response, 
respectively. IgG2c was found to be the dominant isotype, as only a minimal elevation of IgG1 was 
detected in the serum of infected mice but did not show a significant difference between healthy and 
infected mice (Figure 17 g-i). Analysis of the IgG2c response showed a significantly (P<0.0001) 
elevated IgG2c level in the serum of infected animals at 4 weeks p.i. (Figure 17 j). At the same time 
point, the IgG2c level was also significantly (P<0.0001) elevated in streptomycin-pretreated mice 
(Figure 17 k). In both groups, the pathogen-specific IgG2c response was accruing throughout the 
course of the experiment, with antibody levels in antibiotic-pretreated mice being significantly 
(P<0.001) higher at 4 weeks p.i. (Figure 17 l). 
 
3.6.1 IL-22-deficient mice develop increased systemic IgA response against  
S. enterica in the early phase of infection 
To investigate the impact of IL-22 on the systemic S. enterica-specific antibody response, starting 24 
h p.i., peripheral blood was collected every 2 weeks and serum was analyzed by ELISA for  
S. enterica-specific antibodies (IgA, IgM and IgG2c). Analysis of antibody levels allowed investigation 
of the infection status in tested animals, considering its acute and chronic phase. Figure 18 shows the 







Figure 18: Course of the systemic antibody response analyzed in sera of mice infected with S. enterica. Chronic infection 
was induced in wild-type (WT) or IL-22-deficient (IL-22-/-) C57BL/6 mice by oral inoculation with S. enterica (S.e.) with 
administration of a single dose of streptomycin (Strep.; 20 mg/mouse) 24 h prior to infection. Animals treated with PBS 
were used as negative control. Blood was collected from mice every two weeks and serum was prepared and stored at -
80 °C until analysis. Titers of the S. enterica-specific antibodies IgA (a-c), IgM (d-f) and IgG2c (g-i) were determined by ELISA. 
The OD values were measured at 450 nm using a microplate reader (Safire 2, Tecan) and are shown as mean ± SD. Statistics: 
Two-way ANOVA followed by Holm-Sidak’s multiple comparisons test. Number of animals per group: WT Strep. + PBS n=6, 
WT Strep. + S.e. n=11, IL-22-/- Strep. + PBS n=6, IL-22-/- Strep. + S.e. n=12 animals. **P<0.05; ***P< 0.001; ****P< 0.0001. 
 
 
A significantly (P<0.0001) higher level of Salmonella-specific IgA was detected in infected WT mice at 
4 weeks p.i. (Figure 18 a). At the same time point, there was also a significantly elevated (P< 0.0001) 
level of IgA in the serum of IL-22-deficient mice (Figure 18 b). In direct comparison, a significantly 
(P<0.05) higher increase of specific IgA antibodies was observed in IL-22-/- animals if compared to WT 
mice at 2 weeks p.i. (Figure 18 c). Similar to IgA, specific IgM antibodies were significantly increased 
in the serum of infected mice in both WT (P<0.0001) and IL-22-deficient (P<0.001) mice if compared 
to the PBS control group at 4 weeks p.i. (Figure 18 d-e). There were no significant differences in the 
titer of IgM in serum between WT and IL-22-/- mice at any time point of the experiment (Figure 18 f). 





immune response in a later phase of infection. Analysis of the IgG2c response showed a significantly 
(P< 0.0001) elevated level in the serum of infected WT animals at 4 weeks p.i. (Figure 18 g). At the 
same time point, the IgG2c level was also significantly (P< 0.0001) elevated in IL-22-deficient animals 
(Figure 18 h). In both groups, the pathogen-specific IgG2c response increased over the course of the 





























4.1 S. enterica infection in combination with streptomycin pretreatment provides a 
relevant model of intestinal inflammation 
By causing numerous health issues, inflammatory diseases of the GI tract tremendously impair the 
quality of life of many people in both developed and developing countries. Therefore, profound 
understanding of the underlying mechanisms causing chronic inflammation in the intestine is 
indispensable in order to develop appropriate therapeutic and prevention strategies. Since the 
etiology of these disorders is multifactorial and still enigmatic, investigation in appropriate animal 
models with similar disease parameters is essential (133). Interestingly, IBD is often associated with 
an acute inflammatory incident triggered by bacteria or virus infection that disturbs homeostasis of 
the gut and results in dysregulation of the intestinal immune response (134). Considering this, the 
focus of this study was the establishment and scientific characterization of a mouse model using an 
appropriate biological agent to elicit an acute inflammatory reaction in the gut that finally results in 
chronic inflammation.  
By combining a mouse model, which has been shown to be an appropriate tool for investigation of 
the key aspects considering intestinal bacterial infection (132) , with self-developed clinical and 
histopathological score, a comprehensive analysis of the triggered inflammatory reaction as well as 
key aspects of developed colitis was performed. The present study showed that infection of WT 
C57BL/6 mice with an attenuated strain of S. enterica serovar Enteritidis resulted in persistent 
infection with typical symptoms of intestinal inflammation, i.e. an elevated clinical score and 
histopathological aberrations in the colon tissue. Moreover, a single treatment with streptomycin 
one day prior to inoculation with bacteria caused aggravation of colitis symptoms and exacerbated 
histopathological aberrations in the colon tissue in the initial phase of infection. In this study, 
monitoring of colonization in the gut with the pathogen was performed by plating fecal pellets on 
selective XLD agar plates, which allows reliable recognition of Salmonella colonies. The analysis of S. 
enterica load in fecal pellets confirmed the aggravating impact of streptomycin on the acute phase of 
infection by causing significant pathogen colonization within 24 h p.i. These results confirm previous 
findings of Bohnhoff and Miller, who introduced the concept of streptomycin pretreatment for the 
first time (135). Furthermore, colonization of the gut with S. enterica was promoted by antibiotic 





increased susceptibility of WT mice to infection with S. enterica and accelerated development of 
clinical colitis symptoms as already  
shown by other investigators (132). This effect was most likely caused by eradication of the 
physiological microbiota in the gut of these animals by antibiotic pretreatment, which allowed S. 
enterica to colonize more efficiently (136). Clinical signs of intestinal inflammation did not seem to be 
influenced by streptomycin pretreatment in the later phase of infection, since S. enterica load in fecal 
pellets was similar in mice with or without pretreatment starting from 4 weeks p.i. Even though 
streptomycin pretreatment was shown to eliminate >80% of the microbiota from the intestinal tract 
(137), animals most likely managed to partially restore a protective gut microbiota. Disruption of the 
gut microbiota composition has been shown to influence the susceptibility of the host to different 
diseases. IBD is associated with decreased colonization with Faecalibacterium prausnitzii, which is a 
commensal bacterium showing anti-inflammatory effects (138). Disturbed proportions of Firmicutes 
and Bacteroidetes combined with decreased diversity of the gut microbiota has been recognized in 
several mouse models and human patients (139–141) and was associated with the development of 
obesity. Certain species of the intestinal microbiota are promoting cellular immune responses against 
pathogens, e.g. segmented filamentous bacteria (SFB)-induced Th17 responses were shown to be 
competent in fighting intestinal infection with C. rodentium (142). Therefore, the differences 
between pretreated and not pretreated mice in the acute phase of infection observed within our 
study could be substantial in investigating the association between the intestinal microbiome and the 
host.  
Composition of the commensal microbiota is dynamic and susceptible to changes associated with 
age, diet or antibiotic treatment. These factors can alter the gut homeostasis and therefore trigger 
the onset and exacerbation of IBD (143). Several studies have shown that the gut microbiota 
composition is significantly shifted in IBD patients (144, 145). It has also been demonstrated that the 
gut microbiota of patients suffering from IBD consisted of fewer bacterial species and was less stable 
if compared to healthy subjects (146). Moreover, different mouse models of IBD confirmed an 
expansion of Enterobacteriaceae and species belonging to this group, such as Salmonella, which 
altered the host immune defense in order to support their own colonization (147, 148). Additionally, 
many pathogen infections have been linked to the pathogenesis of IBD, particularly Mycobacterium 
paratuberculosis or Escherichia coli (149, 150). Also, an episode of Salmonella gastroenteritis has 
been recognized as a factor increasing the risk to develop IBD (151). According to the results of this 
study, S. enterica infection was able to disturb homeostasis in the gut and elicit an inflammatory 





alterations in the local immune response. Moreover, streptomycin pretreatment had a significant 
impact on the acute and even more explicitly on the chronic phase of inflammatory reaction in situ.  
It has been shown that Salmonella invasion induced T cell activation (102). Furthermore, T cells were 
shown to be important triggers of intestinal inflammation after S. Typhimurium infection and 
depletion of CD3+ T cells significantly attenuated intestinal immune responses against the pathogen 
(152). To analyze the immune response in the colon tissue in more detail, we analyzed T cells and 
inflammatory markers in situ by immunohistochemistry which is a prominent method for identifying 
and locating certain cells and proteins within a tissue, therefore it was possible to confirm that CD3+ 
T cells were significant participants in the intestinal inflammatory reaction against S. enterica. 
Moreover, streptomycin pretreatment enhanced the infiltration of T cells into the tissue not only 4 
weeks, but even more pronounced at 10 weeks p.i. CD4+ T lymphocytes are considered key players 
in the pathogenesis of human IBD, which was confirmed by their infiltration into the inflamed gut 
mucosa in IBD patients. Furthermore, a therapy based on a monoclonal anti-CD4 antibody showed 
efficacy in treatment of patients with chronic steroid-resistant IBD by immediate depletion of CD4 
cells from the circulation (153, 154). Additionally, the essential role of T cells has been demonstrated 
in experimental model of adoptive transfer of naïve T cells into lymphopenic mice (155), which was 
dependent on the presence of the gut microbiota.  
Further investigation of the local intestinal immune response in S. enterica infection confirmed a 
significant role of IFN-, which is an important factor in the host defense against microbial 
pathogens, in particular facultative intracellular bacteria (156). Additionally, mucosal expression of 
IFN- is essential for development and maintenance of the inflammatory reaction. It has been shown 
that this proinflammatory cytokine participates in modulation of the severity of CD (157). We 
demonstrated that S. enterica invasion caused an increase of IFN--producing cells in the gut mucosa 
at 4 weeks p.i. This effect was amplified by streptomycin pretreatment, which induced a further 
increase of IFN- during the first 4 weeks p.i., but also up to 10 weeks p.i. Thus, our findings 
confirmed that IFN- significantly contributes to acute mucosal inflammation (158) and, even more 
important, is a main trigger of chronic gut inflammation in IBD (159).  
IL-22 is a cytokine present on mucosal surfaces and plays an important role in the maintenance of a 
protective barrier. Furthermore, IL-22 is dramatically upregulated in response to various pathogenic 
infections (160). Our study confirmed that infection with S. enterica caused recruitment of IL-22-
producing cells into the gut mucosa. Moreover, streptomycin pretreatment led to significantly 





remarkable in the later phase of the infection, supporting the concept that this cytokine not only 
enhances early host mucosal defense in response to pathogen invasion, but is also an essential part 
of tissue regeneration mechanisms in the chronic phase of infection (56, 161). IL-22 is  
believed to have a strong association with IBD, considering that most of IL-22-associated molecules 
are encoded by IBD susceptibility genes (162). Thus, this cytokine may also have a therapeutic 
potential, especially due to its specific influence on tissue responses with no direct impact on the 
immune system (49).  
The innate immune system plays an essential role in eliminating pathogenic bacteria and maintaining 
a homeostatic environment in the intestinal mucosa (34). However, also the adaptive immune 
system contributes to the first line of defense against enteric invaders by the production of sIgA 
antibodies, which bind pathogens already in the gut lumen (163). Nonetheless, production of sIgA is 
not crucial for pathogen clearance. It has been shown, that IgA-deficient mice infected with S. 
Typhimurium have an equal ability to clear the pathogen from the gut as the wild-type animals (164, 
165). In the present study, sIgA production was not significantly induced at 4 and 10 weeks p.i., 
indicating that in the later phase of S. enterica infection rather the maintenance of homeostasis than 
proinflammatory action is the main role of this antibody. Macpherson et al. demonstrated that even 
though sIgA is the main immunoglobulin present in healthy intestinal mucosa, patients with active 
IBD produce higher concentrations of IgG, but not sIgA. This indicates that relapse of IBD is 
characterized by an exaggerated mucosal antibody response as a result of lost tolerance to the 
commensal microbiota in the gut (166). 
It has been proven that IBD patients presenting the most complex and problematic clinical course of 
disease possess high serum reactivity of IgA and IgG antibodies against intestinal microbes (167). 
Furthermore, production of antibodies against extracellular molecules of gut microorganisms has 
been associated with IBD. Together with specific antibodies directed against certain host structures 
(e.g. antibodies to exocrine pancreas or anti-neutrophil cytoplasmic antibodies (ANCA)), these 
antibodies have been recognized as serum biomarkers for CD and UC (168). In this study, the specific 
humoral immune response against S. enterica (i.e. detection of S. enterica-specific serum antibodies 
levels) was quantified using an ELISA that has been previously developed and validated in our 
laboratory (98). In contrast to the reduced local IgA response in the gut, the production of specific 
systemic IgA was induced by streptomycin pretreatment after 4 weeks p.i. in infected mice. This 
result is in accordance with the fact that secretory and systemic IgA are derived from different 
cellular sources and can be stimulated independently from each other (169, 170). Furthermore, 
streptomycin pretreatment induced a late and transient specific IgM response after S. enterica 





enhanced by antibiotic pretreatment, indicated development of a chronic inflammation caused by 
persisting colonization with the pathogen and driven by Th1 cytokines (171). In contrast, a modest 
specific IgG1 response that was independent of streptomycin pretreatment indicated a weak 
Salmonella-induced Th2 response, obviously not affected by antibiotic pretreatment.  
According to several epidemiologic studies and experimental data, environmental factors play a 
crucial role in the development of IBD. Antibiotic therapy in combination with enteric infections 
potentially impairs the intestinal barrier as well as the composition of the gut microbiota, which are 
key elements in the pathogenesis of IBD (172). Moreover, it has been shown that patients diagnosed 
with IBD were more likely to have received antibiotic therapy 2-5 years before diagnosis (173). Thus, 
the influence of these two factors on the intestinal immune system may be a critical component, 
which should be extensively considered in the management of IBD. Our study introduced a mouse 
model of chronic S. enterica infection with combination of streptomycin pretreatment that facilitated 
to understand the mechanisms involved in the pathophysiology of intestinal inflammation. We 
observed a chronic inflammation in the colon tissue with typical clinical symptoms, immunological 
aberrations and pathohistological features, which are also found in patients suffering from IBD. 
Therefore, one result of this study was the establishment of a relevant model of intestinal 
inflammation that reflects a possible variant of natural etiology of IBD, and thus, could be of great 
benefit for the development of efficient therapeutic strategies in human IBD. 
 
 
4.2 IL-22 plays a protective role in intestinal inflammation by regulating the structure 
and function of the gut barrier 
IL-22 is thought to have a relevant association to intestinal inflammation, including the ability to 
promote mucosal repair and restoration by inducing proliferative and anti-apoptotic pathways as 
well as production of antimicrobial peptides (174). Mucosal healing is one of the current therapeutic 
targets in treatment of IBD. Therefore, further investigation of IL-22 and its clinical relevance 
concerning inflammatory diseases of the gut may clarify the mechanisms involved in IBD 
pathogenesis. IL-22 was shown to be protective to the host in many infectious and inflammatory 
disorders. However, considering its inherent proinflammatory properties, it can also act 
destructively, especially when released in combination with other cytokines, such as IL-17 (161). 
In the first part of this study, investigation of the mouse model of chronic S. enterica infection 
revealed a significant contribution of IL-22 in the immune response against this pathogen in the colon 





increased in IL-22-expressing mice (160). IL-22 has been shown to alleviate infection by some 
pathogens, such as C. rodentium or Plasmodium chabaudi (56, 175), whereas Toxoplasma gondii and 
Listeria monocytogenes infection models revealed its pathogenic character (176, 177). Therefore, the 
second part of this study dealt with the role of IL-22 in the immune response against S. enterica 
infection in the previously established model. In order to explore this question, oral Salmonella 
infection in combination with streptomycin treatment was induced in IL-22-deficient mice. 
The analysis of clinical symptoms after pathogen inoculation with streptomycin pretreatment 
showed that both WT and IL-22-deficient animals were strongly affected by the infection. However, 
considering the stage of disease where symptoms such as weight loss and diarrhea were accruing in 
both groups, the mice with IL-22 deficiency suffered from significantly stronger colitis symptoms. This 
implies a protective function of IL-22 in S. enterica-induced gut inflammation, but only in an early 
phase of the infection. The more pronounced clinical symptoms in the IL-22-deficient mice might 
have been caused by a compromised barrier in the intestinal mucosa and therefore enhanced 
invasion of S. enterica into the colon tissue. This confirms previous findings showing that IL-22 
deficiency leads to facilitated access of pathogenic bacteria into the gut tissue (56). IL-22 promotes 
maintenance of epithelial barrier integrity by inducing production of AMPs, mucus proteins as well as 
strengthening the TJs (60). Thus, the absence of this cytokine might have resulted in impaired 
defense mechanisms against pathogens and therefore increased colonization with S. enterica. This 
hypothesis has been already confirmed in a T cell transfer model, where IL-22 was shown to have a 
protective effect against experimental colitis (178).  
As shown in our model of chronic S. enterica infection, this pathogen colonizes the GI tract causing a 
notable inflammatory reaction in the gut. Therefore, determination of the pathohistological changes 
in the colon tissue was an essential part of the analysis of the role of IL-22 in the management of 
bacteria-induced colitis. WT as well as IL-22-deficient animals showed aberrations in the morphology 
of the colon tissue, which was confirmed by an independent pathologist. Infiltration of immune cells, 
such as lymphocytes, granulocytes and macrophages, along with lesions in the structure of the tissue 
were significant. Similar manifestations characteristic for colitis were previously found in other 
mouse models of IBD as well as in humans (179). Direct comparison of WT and IL-22-deficient mice 
revealed no  
significant differences in the assessed histopathological score, neither in the proximal nor in the 
distal part of the colon. Considering a similar clinical and histopathological score at the end of the 
experiment, IL-22 seems to have an impact in the initial rather than the chronic stage of S. enterica 





gut, where a significantly higher load of the pathogen was observed in IL-22-deficient mice up to 2 
weeks p.i. An important role of IL-22 on the acute-phase response was highlighted by Liang et al., 
who showed influence of this cytokine on systemic biochemical, cellular, and physiological 
parameters and local tissue inflammation (180). IL-22 was shown to play a minor role in the immune 
response during systemic acute infection with Trypanosoma cruzi (181), however its protective 
actions are likely more important at barrier surfaces. Therefore, it would be necessary to test the 
effect of IL-22 deficiency on histological aberrations based on colon tissue collected at early time 
points after S. enterica infection, which could not be accomplished within this study due to the 
limited number of IL-22-deficient mice. 
Production of mucus is a crucial mechanism involved in protection of the intestinal barrier by limiting 
adherence of pathogenic bacteria to the intestinal epithelium. As a consequence, infection and 
inflammation cause an increased activity of mucus-producing goblet cells (182). In order to evaluate 
the production of mucus in the colon tissue of Salmonella-infected mice, a differential staining of 
goblet cells was performed using the broadly accepted histochemical PAS reaction. Interestingly, this 
analysis revealed a decreased amount of mucus in the proximal colon of IL-22-deficient mice, 
whereas in the distal colon it was significantly increased. This is in accordance with the 
histopathological score that was significantly higher in the proximal part of the colon. Normally, 
infection with a pathogen and the consequent inflammatory reaction trigger accelerated secretion of 
mucins. However, prolonged and exhaustive stimulation leads to depletion of goblet cells as well as 
alterations in mucus layers (183). The results of this study indicate stronger inflammation in the 
proximal part of the colon in IL-22-deficient mice, causing loss of goblet cells. In direct comparison of 
WT and IL-22-deficient mice, animals lacking IL-22 showed a significantly decreased amount of mucus 
in the proximal colon. This was also apparent on the PAS-stained cross-sections, where a massive loss 
of goblet cells and alterations of the epithelial cell barrier were observed. A similar impact of IL-22 on 
the regulation of goblet cell differentiation was already shown in a model of intestinal helminth 
infection, where IL-22-deficient mice had reduced expression of MUC2 if compared to WT animals 
(184). These findings suggest a significant function of IL-22 in the maintenance of the mucosal 
barrier. Moreover, it was shown that increased expression of IL-22 improves the condition of goblet 
cells in a spontaneous mouse model of colitis (104). Considering these data, IL-22 seems to play a 
protective role during colitis by preventing loss of mucus-producing cells as well as improving 
structure and function of the mucosal barrier in the intestine which is reflected in our in vivo model. 
In addition to the analysis of pathohistological aberrations and production of mucus by goblet cells, 
immunohistochemical staining of certain immune cells and markers was performed to characterize 





infiltration of CD3+ cells in the model of S. enterica-induced colitis, it was interesting to determine the 
impact of IL-22 on T cell recruitment into the inflamed colonic tissue. It has already been shown that 
IL-22 diminishes the T cell response in an experimental model of malaria (185) and that IL-22 plays a 
protective role in T-cell mediated hepatitis (186). However, IL-22 deficiency did not cause any 
changes in CD3 expression. The IL-22 receptor is only present on non-hematopoietic cells, therefore 
this cytokine can particularly act on epithelial cells, keratinocytes, and hepatocytes (161). Thus, a 
direct influence of IL-22 on the infiltration of T lymphocytes can be excluded and the function of IL-22 
in the GI tract should be related to the maintenance of the epithelial barrier, which supports our 
results of decreased production of mucus in IL-22-deficient mice. 
RORt is expressed by various cell types, but primarily by potentially IL-22-producing cells, such as 
Th22, Th17, and ILC3 (49). Treg cells expressing RORt were shown to act as stable suppressive 
agents on T effector cells during intestinal inflammation (187). Accordingly, we observed a 
significantly increased expression of this transcription factor in colon tissue of mice suffering from 
bacteria-induced colitis. Additionally, infiltration of RORt+ cells was notably stronger in the proximal 
colon of IL-22-deficient mice if compared to the WT group. Enhanced production of IL-22 by ILCs and 
δT cells due to induced binding of RORt to the IL-22 promoter has been reported to attenuate 
colitis in a mouse model of C. rodentium infection (188). In S. enterica-induced intestinal 
inflammation, an increased expression of RORt could be explained by the stronger inflammatory 
reaction in the proximal part of the colon due to IL-22 deficiency. However, in order to reveal the 
identity of RORt-expressing cells, they would have to be further characterized by specific markers 
for Th22, Th17, and ILC3. Additionally, double immunohistochemical staining could be helpful to 
analyze cells responsible for the massive IL-22 expression in the colon tissue of S. enterica-infected 
mice, which was observed in the first part of the study. 
The intestinal epithelial monolayer plays a crucial role in preventing invasion of pathogenic bacteria 
into the tissue by forming a protective mucus barrier. Claudins are membrane proteins that are 
major structural components of TJs forming the seal between epithelial cells, thereby maintaining 
the structure of the epithelial barrier (189). Inflammation of the intestinal tissues is  
associated with altered TJs structures and increased permeability as well as increased production of 
IL-22 (64). In this study, it was shown that IL-22-deficient mice suffering from S. enterica-induced 
colitis have a reduced expression of Claudin-1 in the colon tissue if compared to WT animals, which 
was significantly pronounced in the proximal part of the colon. This result  
suggests a meaningful function of IL-22 in the regulation of intestinal epithelial barrier permeability 
by regulation of Claudin-1 expression under inflammatory conditions. Other investigators previously 





Claudin-1 (190). Using semiquantitative immunohistochemical staining of Claudin-1 in the mouse 
model of the bacteria-induced colitis, this study confirmed a stimulating action of IL-22 on the 
Claudin-1 levels in vivo. This result is in agreement with the clinical score, which was higher for the IL-
22-deficient animals, implying that deficiency of IL-22 led to aggravated clinical symptoms due to an 
altered intestinal epithelial barrier function and consequently facilitated bacterial invasion. Loss of TJ 
proteins and consequently a weakened gut barrier was also observed in IBD patients (191). The 
impact of IL-22 on the expression of Claudin-1 further confirms a protective role of this cytokine 
during inflammation of the GI tract. 
IL-22 is known to significantly contribute to the host defense against microbes at mucosal sites. Its 
role in promoting protective systemic immune responses against Clostridium difficile was reported to 
be critical (192). However, this study did not reveal any significant impact of IL-22 on the specific 
systemic adaptive immunity against S. enterica. Merely production of Salmonella-specific IgA serum 
antibodies was significantly faster and higher in IL-22-deficient mice 14 days p.i. However, it was 
approximately at the same level as in WT animals at day 29 p.i. It is noteworthy that structure and 
function of IgA present in the serum is notably different to IgA produced in the gut mucosa, which 
has a direct impact on bacterial colonization, e.g. through obstruction of anchorage to the mucosal 
cells. In contrast, systemic IgA is additionally produced in bone marrow and upon binding triggers 
mechanisms that lead to impairment of pathogenic microbes (193). Therefore, immunohistochemical 
staining of S. enterica-specific IgA in the intestinal tissue should be performed in the future.  
In recent years, the role of IL-22 in the defense against bacterial and viral infections has been studied 
in a number of models. Our study provides results that foster the protective function of this cytokine 
in intestinal infection. It has been shown that IL-22 ameliorates intestinal inflammation in the mouse 
T-cell transfer and DSS models (178). Here, we demonstrate a similar protective action of IL-22 in the 
bacteria-induced model of colitis. To further investigate the possible therapeutic potential of IL-22, 
local treatment of the inflamed gut of S. enterica-infected mice with exogenous IL-22 would be a 
suitable approach. A novel microinjection-based local gene-delivery system that is capable of 
targeting the inflamed intestine might be a useful for this purpose (59). Thus, detailed analysis of IL-
22 function in the intestinal mucosa as well as the microbiota could be aimed in further studies using 






4.3 Streptomycin-mediated eradication of the commensal microbiota caused a more 
pronounced and long-lasting Th1 response 
Infection with S. enterica triggers a rapid innate and adaptive immune response. Even though 
Salmonella inhabits intra-macrophage phagosomes, the T cell response is believed to be essential for 
resolving the infection (100). Th1 cytokines, e.g. IFN- and TNF-α, play a crucial role in the early 
stages of infection by inducing the production of reactive oxygen by macrophages as well as other 
mechanisms promoting confinement and clearance of the pathogen (98, 194). It has been shown 
that mice lacking IFN- have a significantly compromised ability to resolve S. enterica infection (195). 
One of the major sources of IFN- is represented by activated S. enterica-specific effector T cells, 
which are indispensable for control of primary and secondary Salmonella infections (98). Oral 
infection of mice triggers the activation of antigen-specific T cells in PPs and MLNs. Activated T cells 
acquire Th1 effector functions to finally stimulate infected macrophages through the release of IFN- 
(100). Furthermore, an effective immune response against S. enterica infection requires the 
contribution of B lymphocytes that are stimulated by inflammatory cytokines to produce S. enterica-
specific antibodies (98, 196, 197). Our study of the model of S. enterica-induced colitis revealed a 
significant contribution of IFN--producing cells in the local immune response in the intestinal tissue. 
Unexpectedly, streptomycin pretreatment induced a further increase of these cells during the first 4 
weeks p.i. that was sustained up to 10 weeks p.i. This result confirmed that IFN- efficiently 
contributes to acute mucosal inflammation (158) and supports the assumption that IFN- is a main 
trigger of chronic gut inflammation in IBD (159). Th1 cells represent the major source of IFN- during 
chronic inflammation, suggesting a strong Th1 bias following streptomycin pretreatment. It was 
shown that survival of S. Typhimurium infection required activation of macrophages by a Th1 
response (198). In addition, IFN- signaling was shown to be essential for the confinement of 
pathogen load in the mucosa (199). Our data promotes the concept that IFN- is one of the key 
factors in chronic S. enterica infection controlling the immune status of persistently infected mice. 
The chronically high pathogen load in bacterial faeces indicated that the infection could not be 
cleared and consequently, IFN- was continuously produced to activate infected macrophages. 
However, expression of this cytokine was not elevated in the tissue of mice not pretreated with the 
antibiotic. Thus, streptomycin pretreatment most likely led to the dominance of S. enterica over 
commensals in the early phase of infection. As a consequence, S. enterica-specific IFN--producing 
(Th1) cells were activated and maintained their activity throughout the chronic infection phase. In 
the course of infection without antibiotic pretreatment, the competing exclusion principle prevented 
invasion of S. enterica and consequently critically increased and prolonged S. enterica-specific Th1 





caused significantly decreased sIgA production in the gut mucosa. In combination with the finding of 
an increased number of IFN--producing cells this suggests that streptomycin promotes a Th1 
immune response in the colon tissue. This is supported by the fact that IFN- inhibits the 
development of IgA-producing B cells in the gut and thus reduces the delivery of sIgA (200). 
Furthermore, the tendency towards a Th1 response in this model might have inhibited sufficient 
production of sIgA, since B cell differentiation in Peyer’s patches requires production of Th2 
cytokines (201). In mice, the Th2 cytokine IL-5 represents an important co-factor for the production 
of IgA. (202) This study showed that streptomycin not only exacerbated the inflammatory response 
to S. enterica infection, but also promoted a local Th1 response against pathogens in the colon as 
illustrated by a contemporaneous increase of IFN--producing cells and decreased production of sIgA 
in the gut. This was also confirmed by the profile of systemic S. enterica-specific IgG1 and IgG2c 
antibody responses. S. enterica-infected mice developed increased levels of Salmonella-specific  
IgG2c but no IgG1 serum antibodies, indicating a dominant activity of the Th1 lymphocyte 
subpopulation (98). The same effect was observed after administration of streptomycin prior to 
infection, thus pretreatment with antibiotic did not influence the systemic Th1/Th2 balance in this 
model. However, streptomycin pretreatment prolonged the occurrence of a robust local Th1 
response in the gut, which might be critical for the development of chronic colitis in this model. 
Further investigation of the involved T cell subsets and cytokines could reveal the influence of 
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An appropriate immune response in the intestine against commensal and pathogenic bacteria 
primarily depends on the intestinal immune system. Presence of the microbiota is essential for an 
appropriate function of the intestinal immune system and can be severely disrupted by antibiotic 
treatment, leading to disturbance of the balance between tolerance and immunity and possibly to 
serious chronic conditions, e.g. IBD. Therefore, the aim of this study was to establish a bacteria-
induced mouse model of human IBD applicable for investigation of the role of commensal versus 
pathogenic bacteria in the onset and development of chronic intestinal inflammation.  
The mouse model introduced in the present work focused on chronic inflammatory reaction 





infection were analyzed. Additionally, it was investigated, whether antibiotic treatment prior to 
infection has a significant impact on the course of the systemic or local mucosal immune response 
against S. enterica. Due to the significant increase of the IL-22 level reported from IBD patients, and 
the assumed crucial role of this immunoregulatory cytokine for human IBD a special focus of this 
study was to analyze the role of IL-22 in the established mouse model of bacteria-induced chronic 
colitis. 
Inoculation of C57BL/6 mice with S. enterica subsequently to streptomycin treatment resulted in a 
persistent infection and chronic inflammation in the intestine. Antibiotic pretreatment significantly 
aggravated clinical symptoms and histological features, particularly in the acute phase of infection. 
IL-22 deficiency caused further exacerbation of the symptoms. An impact of streptomycin 
pretreatment on the early phase of infection was also confirmed by a significantly increased 
presence of bacteria in faecal pellets up to 2 weeks p.i. Mice lacking IL-22 were more susceptible to 
colonization with S. enterica, particularly in the early phase of infection. Streptomycin pretreatment 
caused aggravation of pathohistological changes in the colon tissue caused by oral infection with S. 
enterica. IL-22 deficiency had no significant impact on histological aberrations. However, it increased 
loss of mucus-producing goblet cells, which is a typical symptom of an inflammatory reaction in the 
colon tissue. Analysis of the local immune response against S. enterica showed that antibiotic 
pretreatment significantly promoted infiltration of T cells into the colon tissue in both the acute and 
the chronic phase of infection. Streptomycin pretreatment resulted in a significant alteration of IL-22 
production in the colon. Furthermore, the number of IFN--producing cells and the production of 
secretory IgA were significantly altered following streptomycin pretreatment. Although, IL-22 
deficiency had no impact on T cell recruitment it compromised the intestinal epithelial barrier of S. 
enterica- infected mice by reducing the level of claudin-1 in the gut epithelium. Additionally, the 
number of RORt-producing cells was significantly increased in the colon tissue of mice lacking IL-22. 
An impact of streptomycin pretreatment on the S. enterica-specific systemic antibody response 
resulted in increased levels of IgA and IgM serum antibodies in the early phase of infection. A 
continuously rising IgG2c response up to 10 weeks p.i was also observed, however was not 
dependent on administration of the antibiotic. IL-22-deficient mice developed a significantly 
increased systemic IgA response against S. enterica in comparison to WT animals. 
In summary, this study convincingly demonstrates that antibiotic pretreatment exacerbates the 
inflammatory reaction against S. enterica. Combination of S. enterica infection with  
streptomycin pretreatment results in a chronic inflammation of the colon tissue with typical clinical 
symptoms, immunological aberrations, and pathohistological features that are characteristic for IBD. 





reflect a possible scenario of the pathogenesis of human IBD. The present study emphasizes a 
protective role of IL-22 in intestinal inflammation and its crucial function in maintenance of the gut 
barrier, therefore further extended analysis of its role in intestinal mucosa should be performed in 
future studies using this in vivo model. 
Interestingly, this work showed that eradication of gut microbiota resulting from treatment with 
streptomycin triggers a more pronounced and robust Th1 response against S. enterica infection. This 
effect might be crucial for the development of chronic colitis in this model and should be further 
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